UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30, 2019~~March 31, 2020

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 001-38129

Mersana Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		04‑3562403
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

840 Memorial Drive Cambridge, MA 02139

(Address of principal executive offices)

(Zip Code)

(617) 498‑0020

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	MRSN	The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes ☐ No ☒.

There were ~~47,883,522~~58,949,470 shares of Common Stock ($0.0001 par value per share) outstanding as of ~~November 4, 2019.~~May 5, 2020.

Table of Contents

Unless otherwise stated or the context requires otherwise, all references to “us,” “our,” “we,” the “Company” and similar designations in this Quarterly Report on Form 10-Q refer to Mersana Therapeutics, Inc. and its consolidated subsidiary, Mersana Securities Corp.

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward‑looking statements. Forward‑looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. The words “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” ~~“seek,~~“on track,” “plan,” “possible,” “potential,” “predict,” “project,” ~~“target,~~“seek,” ~~“potential,~~“should,” “target,” “will,” ~~“would,” “possible,” “could,” “should,” “continue,” “contemplate”~~“would” or the negative of these terms or other similar expressions are intended to identify forward‑looking statements, although not all forward‑looking statements contain these identifying words.

These forward‑looking statements ~~may~~ include, among other things, statements about:

the initiation, cost, timing, progress and results of our current and future research and development activities and preclinical ~~studies~~ and clinical ~~trials;~~

~~the potential benefits of strategic partnership agreements and our ability to enter into selective strategic partnership arrangements;~~studies;

the timing of, and our ability to obtain and maintain, regulatory approvals for our product candidates;

unmet need of ovarian cancer and non-small cell lung cancer;

our ability to quickly and efficiently identify and develop additional product candidates;

our ability to advance any product candidate into, and successfully complete clinical ~~trials;~~studies;

our intellectual property position, including with respect to our trade secrets; ~~and~~

the potential benefits of strategic partnership agreements and our ability to enter into selective strategic partnerships;

our estimates regarding expenses, future revenues, capital requirements, the sufficiency of our current and expected cash resources and our need for additional ~~financing.~~financing; and

the potential impact of the ongoing COVID-19 pandemic.

We may not actually achieve the plans, intentions or expectations disclosed in our forward‑looking statements, and you should not place undue reliance on our forward‑looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward‑looking statements we make. We have included important factors in the cautionary statements included in our Annual Report on Form 10-K for the year ended December 31, 2019 and in this Quarterly Report on Form 10-Q, particularly in the “Risk Factors” ~~section,~~sections, that we believe could cause actual results or events to differ materially from the forward‑looking statements that we make. Our forward‑looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.

In addition, while we expect that the COVID-19 pandemic might adversely affect our preclinical and clinical development efforts, business operations and financial results, the extent of the impact and the value of and market for our common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, physical distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease.

The forward‑looking statements contained herein represent our views as of the date of this Quarterly Report on Form 10-Q. We anticipate that subsequent events and developments ~~may~~will cause our views to change. ~~However, we disclaim any obligation to update these forward‑looking statements, except to the extent required by applicable law.~~ You should, therefore, not rely on these forward‑looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form 10-Q.

Table of Contents

TABLE OF CONTENTS


	Page
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements (unaudited)
Condensed Consolidated Balance Sheets as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018~~2019	4
Condensed Consolidated Statements of Operations and Comprehensive ~~Loss~~Income (Loss) for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~	5
Condensed Consolidated Statement of Stockholders’ Equity for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~	6
Condensed Consolidated Statements of Cash Flows for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~	7
Notes to Condensed Consolidated Financial Statements	8
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	2523
Item 3. Quantitative and Qualitative Disclosures About Market Risk	3331
Item 4. Controls and Procedures	3332
PART II - OTHER INFORMATION	3533
Item 1. Legal Proceedings	3533
Item 1A. Risk Factors	3533
Item 6. Exhibits	35
Signatures	36

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Mersana Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

(unaudited)


	September 30,		December 31,		March 31,		December 31,
	2019		2018		2020		2019
Assets
Current assets:
Cash and cash equivalents	$	58,196	$	59,634	$	60,450	$	62,351
Short-term marketable securities		53,806		10,497		17,976		37,439
Accounts receivable		298		459
Prepaid expenses and other current assets		2,397		3,715		1,866		1,536
Total current assets		114,697		74,305		80,292		101,326
Property and equipment, net		2,446		2,694		1,979		2,164
Operating lease right-of-use assets		3,059		—		12,134		2,598
Other assets		1,453		1,503		1,453		1,453
Total assets	$	121,655	$	78,502	$	95,858	$	107,541
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	7,304	$	10,727	$	4,603	$	7,296
Accrued expenses		8,037		12,375		5,678		8,986
Deferred revenue		4,646		46,196		4,804		4,815
Operating lease liabilities		2,145		—		1,150		2,219
Short-term debt		167		—		1,167		667
Other liabilities		85		127		88		87
Total current liabilities		22,384		69,425		17,490		24,070
Operating lease liabilities		1,257		—		11,295		677
Long-term debt, net		4,670		—		3,732		4,201
Other liabilities		299		282		250		275
Total liabilities		28,610		69,707		32,767		29,223
Commitments (Note 11)
Stockholders' equity
Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively		—		—
Common stock, $0.0001 par value; 175,000,000 shares authorized; 47,882,897 and 23,234,472 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively		5		3
Commitments (Note 12)
Stockholders' equity:
Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively						—		—
Common stock, $0.0001 par value; 175,000,000 shares authorized; 48,006,049 and 45,388,023 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively						5		5
Additional paid-in capital		269,140		172,966		272,390		270,662
Accumulated other comprehensive income (loss)		28		(8)		(4)		25
Accumulated deficit		(176,128)		(164,166)		(209,300)		(192,374)
Total stockholders’ equity		93,045		8,795		63,091		78,318
Total liabilities and stockholders’ equity	$	121,655	$	78,502	$	95,858	$	107,541

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Mersana Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive ~~Loss~~Income (Loss)

(in thousands, except share and per share data)

(unaudited)


	Three months ended				Nine months ended				Three months ended
	September 30,				September 30,				March 31,
		2019		2018		2019		2018		2020		2019

Collaboration revenue	$	844	$	2,151	$	42,081	$	9,405	$	11	$	41,035
Operating expenses:
Research and development		13,701		15,180		42,610		40,098		12,219		15,143
General and administrative		4,436		4,380		13,072		12,181		4,936		4,443
Total operating expenses		18,137		19,560		55,682		52,279		17,155		19,586
Other income (expense):
Interest income		608		340		1,785		1,049		306		452
Interest expense		(107)		—		(146)		—		(88)		—
Total other income (expense), net		501		340		1,639		1,049		218		452
Net loss		(16,792)		(17,069)		(11,962)		(41,825)
Other comprehensive loss:
Unrealized gain on marketable securities		17		48		36		107
Comprehensive loss	$	(16,775)	$	(17,021)	$	(11,926)	$	(41,718)
Net loss attributable to common stockholders — basic and diluted	$	(16,792)	$	(17,069)	$	(11,962)	$	(41,825)
Net loss per share attributable to common stockholders — basic and diluted	$	(0.35)	$	(0.74)	$	(0.28)	$	(1.82)
Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — basic and diluted		47,833,607		23,152,019		42,011,340		22,979,516
Net income (loss)										(16,926)		21,901
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities										(29)		8
Comprehensive income (loss)									$	(16,955)	$	21,909
Net income (loss) attributable to common stockholders — basic and diluted									$	(16,926)	$	21,901
Net income (loss) per share attributable to common stockholders — basic									$	(0.35)	$	0.72
Net income (loss) per share attributable to common stockholders — diluted									$	(0.35)	$	0.70
Weighted-average number of shares of common stock used in net income (loss) per share attributable to common stockholders — basic										47,988,630		30,299,650
Weighted-average number of shares of common stock used in net income (loss) per share attributable to common stockholders — diluted										47,988,630		31,461,696

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Mersana Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

(unaudited)



				Additional		Accumulated									Additional		Accumulated
	Common Stock			Paid-in		Other Comprehensive		Accumulated		Stockholders’		Common Stock			Paid-in		Other Comprehensive		Accumulated		Stockholders’
	Shares	Amount		Capital		Income (Loss)		Deficit		Equity		Shares	Amount		Capital		Income (Loss)		Deficit		Equity
Balance at December 31, 2017	22,765,017	$	3	$	168,018	$	(149)	$	(97,878)	$	69,994
Cumulative effect adjustment for adoption of ASC 606	—		—		—		—		(2,031)		(2,031)
Exercise of stock options	104,945		—		255		—		—		255
Stock-based compensation expense	—		—		745		—		—		745
Other comprehensive loss	—		—		—		(13)		—		(13)
Net loss	—		—		—		—		(12,403)		(12,403)
Balance at March 31, 2018	22,869,962		3		169,018		(162)		(112,312)		56,547
Exercise of stock options	247,776		—		470		—		—		470
Stock-based compensation expense	—		—		958		—		—		958
Other comprehensive income	—		—		—		72		—		72
Net loss	—		—		—		—		(12,354)		(12,354)
Balance at June 30, 2018	23,117,738		3		170,446		(90)		(124,666)		45,693
Exercise of stock options	43,137		—		128		—		—		128
Stock-based compensation expense	—		—		1,053		—		—		1,053
Other comprehensive income	—		—		—		48		—		48
Net loss	—		—		—		—		(17,069)		(17,069)
Balance at September 30, 2018	23,160,875		3		171,627		(42)		(141,735)		29,853
Exercise of stock options	31,411		—		65		—		—		65
Purchase of common stock under ESPP	42,186		—		146		—		—		146
Stock-based compensation expense	—		—		1,128		—		—		1,128
Other comprehensive income	—		—		—		34		—		34
Net loss	—		—		—		—		(22,431)		(22,431)
Balance at December 31, 2018	23,234,472		3		172,966		(8)		(164,166)		8,795	23,234,472	$	3	$	172,966	$	(8)	$	(164,166)	$	8,795
Exercise of stock options	12,192		—		42		—		—		42	12,192		—		42		—		—		42
Issuance of common stock under public offering, net of issuance costs of $5,587	24,437,500		2		92,160		—		—		92,162	24,437,500		2		92,160		—		—		92,162
Stock-based compensation expense	—		—		1,164		—		—		1,164	—		—		1,164		—		—		1,164
Other comprehensive income	—		—		—		8		—		8	—		—		—		8		—		8
Net income	—		—		—		—		21,901		21,901	—		—		—		—		21,901		21,901
Balance at March 31, 2019	47,684,164		5		266,332		—		(142,265)		124,072	47,684,164		5		266,332		—		(142,265)		124,072
Exercise of stock options	32,693		—		58		—		—		58	32,693		—		58		—		—		58
Purchase of common stock under ESPP	82,281		—		283		—		—		283	82,281		—		283		—		—		283
Stock-based compensation expense	—		—		1,161		—		—		1,161	—		—		1,161		—		—		1,161
Other comprehensive income	—		—		—		11		—		11	—		—		—		11		—		11
Net loss	—		—		—		—		(17,071)		(17,071)	—		—		—		—		(17,071)		(17,071)
Balance at June 30, 2019	47,799,138		5		267,834		11		(159,336)		108,514	47,799,138		5		267,834		11		(159,336)		108,514
Exercise of stock options and warrants	83,759		—		21		—		—		21	83,759		—		21		—		—		21
Stock-based compensation expense	—		—		1,285		—		—		1,285	—		—		1,285		—		—		1,285
Other comprehensive income	—		—		—		17		—		17	—		—		—		17		—		17
Net loss	—		—		—		—		(16,792)		(16,792)	—		—		—		—		(16,792)		(16,792)
Balance at September 30, 2019	47,882,897	$	5	$	269,140	$	28	$	(176,128)	$	93,045	47,882,897		5		269,140		28		(176,128)		93,045
Retirement of common stock in exchange for common stock warrant												(2,575,000)		—		(8,986)		—		—		(8,986)
Issuance of common stock warrant in exchange for retirement of common stock												—		—		8,986		—		—		8,986
Purchase of common stock under ESPP												57,792		—		206		—		—		206
Exercise of stock options and warrants												22,334		—		54		—		—		54
Stock-based compensation expense												—		—		1,262		—		—		1,262
Other comprehensive loss												—		—		—		(3)		—		(3)
Net loss												—		—		—		—		(16,246)		(16,246)
Balance at December 31, 2019												45,388,023		5		270,662		25		(192,374)		78,318
Exercise of common stock warrant in exchange for common stock												2,574,971		—		—		—		—		—
Exercise of stock options and warrants												43,055		—		119		—		—		119
Stock-based compensation expense												—		—		1,609		—		—		1,609
Other comprehensive loss												—		—		—		(29)		—		(29)
Net loss												—		—		—		—		(16,926)		(16,926)
Balance at March 31, 2020												48,006,049	$	5	$	272,390	$	(4)	$	(209,300)	$	63,091

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Mersana Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)


	Nine months ended				Three months ended
	September 30,				March 31,
	2019		2018		2020		2019
Cash flows from operating activities
Net loss	$	(11,962)	$	(41,825)
Adjustments to reconcile net loss to net cash used in operating activities:
Net income (loss)					$	(16,926)	$	21,901
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation		963		907		248		337
Loss on disposal of fixed assets		—		20
Net amortization of premiums and discounts on investments		(87)		(288)		(66)		4
Stock-based compensation		3,610		2,756		1,609		1,164
Non-cash rent expense		—		77
Non-cash interest expense		65		—
Other non-cash items						37		26
Changes in operating assets and liabilities:
Accounts receivable		161		198		—		(9)
Prepaid expenses and other current assets		1,318		(1,379)		(330)		389
Other assets		—		(1,433)
Accounts payable		(3,102)		3,619		(2,693)		(3,444)
Accrued expenses		(4,518)		3,568		(3,128)		(4,463)
Operating lease assets and liabilities		(66)		—
Operating lease assets						444		—
Operating lease liabilities						(430)		—
Deferred revenue		(41,550)		(5,532)		(11)		(40,592)
Net cash used in operating activities		(55,168)		(39,312)		(21,246)		(24,687)

Cash flows from investing activities
Maturities of marketable securities		10,500		74,565		19,500		10,500
Purchase of marketable securities		(53,688)		—
Purchase of property and equipment		(605)		(1,093)		(65)		(372)
Net cash provided by (used in) investing activities		(43,793)		73,472
Net cash provided by investing activities						19,435		10,128

Cash flows from financing activities
Net proceeds from public offering of common stock		92,162		—		—		92,162
Proceeds from exercise of stock options		121		853		119		42
Proceeds from purchases of common stock under ESPP		283		—
Proceeds from issuance of debt, net of issuance costs		4,965		—
Payments from issuance of debt						(180)		—
Payments under capital lease obligations		(58)		—		(29)		—
Net cash provided by financing activities		97,473		853
Net cash provided by (used in) financing activities						(90)		92,204

Increase (decrease) in cash, cash equivalents and restricted cash		(1,488)		35,013		(1,901)		77,645
Cash, cash equivalents and restricted cash, beginning of period		60,005		26,962		62,672		60,005
Cash, cash equivalents and restricted cash, end of period	$	58,517	$	61,975	$	60,771	$	137,650

Supplemental disclosures of non-cash activities:
Purchases of property and equipment in accounts payable and accrued expenses	$	—	$	75	$	—	$	26
Debt financing costs in accrued expenses	$	180	$	—
Cash paid for interest	$	64	$	—	$	56	$	—
Property and equipment acquired under finance leases	$	429	$	—
Adjustment to accumulated deficit and deferred revenue upon adoption of Topic 606	$	—	$	2,031
Right-of-use assets obtained in exchange for operating lease liabilities					$	9,980	$	4,369
Right-of-use assets obtained in exchange for financing lease liabilities					$	—	$	429

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements

(in thousands, except share and per share data)

(unaudited)

1. Nature of business and basis of presentation

Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company ~~located in Cambridge, Massachusetts. The Company is~~ focused on developing antibody drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with significant unmet need. The Company has leveraged ~~over~~ 20 years of industry learning in the ADC field to develop proprietary ~~technologies~~and differentiated technology platforms that enable it to design ADCs to have improved efficacy, safety and tolerability relative to existing ADC therapies. The Company’s innovative platforms which include Dolaflexin and Dolasynthen, each delivering its DolaLock payload, as well as Immunosynthen, delivering a novel ~~platform, Dolaflexin,~~stimulator of interferon genes (STING) agonist, provide an efficient product engine that has ~~been used to generate proprietary ADC~~enabled a robust discovery pipeline for the Company and its partners. The Company’s product candidates ~~to address patient populations that are not currently amenable to treatment with traditional ADC‑based therapies. The~~include XMT‑1536 and XMT-1592. XMT-1536, an ADC utilizing the Company’s ~~lead product candidate, XMT‑1536, is a first-in-class, wholly-owned~~ Dolaflexin ~~ADC~~platform and targeting NaPi2b, an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) ~~adenocarcinoma. In August 2019, the Company announced the dosing of the first patient~~adenocarcinoma is currently in the expansion portion of ~~the~~a Phase 1 study ~~of XMT-1536. The expansion cohorts will assess the efficacy, safety and tolerability of XMT-1536 at 36 mg/m~~2 ~~every four weeks~~ in patients with ~~platinum-resistant~~ ovarian cancer and ~~non-small cell lung cancer (NSCLC)~~NSCLC adenocarcinoma. XMT-1592 uses one of the Company’s new platforms, Dolasynthen, and also targets NaPi2b. The Company ~~has not yet determined a maximum tolerated dose, and it plans to continue the dose escalation portion of the study~~filed an Investigational New Drug (IND) application in ~~parallel.~~

In January 2019, following a strategic evaluation by the Company of the competitive environment for HER2-targeted therapies, the Company and its former partner, Takeda Pharmaceutical Company Limited, or Takeda, decided to discontinue the development of XMT-1522, which was then being studied in the dose escalation portion of a Phase 1 clinical trial. The Company’s collaboration agreements with Takeda were terminated during the first quarter of 2020, which was approved by the U.S. Food and Drug Administration (FDA). The Company remains on track to initiate the Phase 1 dose escalation study of XMT-1592 in the second quarter of 2020.

The Company has incurred cumulative net losses since inception. For the three months ended March 31, 2020, the net loss was $16,926, compared to net income of $21,901 in the three months ended March 31, 2019. The difference year over year is primarily attributable to $39,965 in revenue that was recognized in the first quarter of 2019 as a result of the discontinuation of the partnership with Takeda in the first quarter of 2019. The Company expects to continue to incur operating losses for at least the next several years. As of March 31, 2020, the Company had an accumulated deficit of $209,300. The future success of the Company is dependent on, among other factors, its ability to identify and develop its product candidates, and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative operating cash flows have had, and will continue to have, an adverse effect on the Company’s stockholders' equity and working capital.

On April 7, 2020, the Company sold 8,938,599 and 1,962,000 shares of common stock at $5.59 per share and $7.74 per share, respectively, to raise gross proceeds of $65,153 through its at-the-market equity offering program (ATM). The Company believes that its currently available funds will be sufficient to fund the Company’s operations through at least the next twelve months from the issuance of this Quarterly Report on Form 10-Q. Management’s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management’s estimates, the Company may need to seek additional funding.

The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, the need for additional capital, risks of failure of preclinical ~~studies~~ and clinical ~~trials,~~studies, the need to obtain marketing approval and reimbursement for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, reliance on third party manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.

The Company has incurred cumulative net losses since inception. For the nine months ended September 30, 2019, the net loss was $11,962, compared to $41,825 in the nine months ended September 30, 2018. The difference year over year is primarily attributable to $39,965 in revenue that was recognized in the first quarter of 2019 as a result of the discontinuation of the partnership with Takeda in the first quarter of 2019. The Company did not recognize any revenue related to the collaboration agreements with Takeda in the second or third quarter of 2019 and does not expect to have any further revenue related to these agreements.

Cash used in operations was $55,168 for the nine months ended September 30, 2019 and $39,312 for the nine months ended September 30, 2018. The Company expects to continue to incur operating losses and negative operating cash flows for the foreseeable future. As of September 30, 2019, the Company had an accumulated deficit of $~~176,128. The future success of the Company is dependent on its ability to identify and develop its product candidates and ultimately upon its ability to attain profitable operations.~~ The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. The Company’s net losses may fluctuate significantly from quarter to quarter and year to year. Net losses and negative operating cash flows have had, and will continue to have, an adverse effect on the Company’s stockholders' equity and working capital. The Company believes that its cash, cash equivalents, and marketable securities, as of September 30, 2019, will enable it to fund its operating plan through at least mid-2021. Management’s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management’s estimates, the Company may need to seek additional funding.

~~The~~ Company’s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification

~~Table of Contents~~

~~Mersana Therapeutics, Inc.~~

~~Notes to condensed consolidated financial statements (continued)~~

~~(in thousands, except share and per share data)~~

~~(unaudited)~~

(ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). All dollar amounts, except per share data in the text and tables herein, are stated in thousands unless otherwise indicated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(in thousands, except share and per share data)

(unaudited)

ended December 31, ~~2018~~2019 and the notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2018~~2019 filed with the SEC on ~~March 8, 2019.~~February 28, 2020.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position as of ~~September 30, 2019,~~March 31, 2020, the results of its operations for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018,~~ a statement of stockholders’ equity for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ and cash flows for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 and ~~2018.~~2019. Such adjustments are of a normal and recurring ~~nature, other than the adjustments associated with the adoption of ASC 842,~~ ~~Leases~~ ~~(ASC 842).~~nature. The results for the three ~~and nine~~ months ended ~~September 30, 2019~~March 31, 2020 are not necessarily indicative of the results for the year ending December 31, ~~2019,~~2020, or for any future period.

~~Effective January 1, 2019, the Company adopted the requirements of ASC 842 using the modified retrospective method as discussed below in Note 2: Summary of Significant Accounting Policies.~~

2. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include those of the Company and its wholly-owned subsidiary, Mersana Securities Corp. All intercompany balances and transactions have been eliminated.

Use of Estimates

The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates which include, but are not limited to, management’s judgments with respect to the identification of performance obligations and ~~estimated~~standalone selling prices of those performance obligations within its revenue arrangements, accrued expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker, or decision making group, in deciding how to allocate resources and assess performance. The Company ~~operates~~views its operations and manages its business as a single operating segment, which is the business of discovering and developing ADCs.

Summary of Accounting Policies

The significant accounting policies used in preparation of these condensed consolidated financial statements for the three ~~and nine~~ months ended ~~September 30, 2019~~March 31, 2020 are consistent with those discussed in Note 2 to the consolidated financial statements in the Company’s ~~2018~~2019 Annual Report on Form ~~10-K, except as noted below with respect to the Company’s lease accounting policies and as disclosed within the “Recently Issued Accounting Pronouncements” section below.~~

~~Table of Contents~~

~~Mersana Therapeutics, Inc.~~

~~Notes to condensed consolidated financial statements (continued)~~

~~(in thousands, except share and per share data)~~

~~(unaudited)~~

10-K.

Fair Value Measurements

Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820 Fair Value Measurement (ASC 820) establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

Level 1—Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(in thousands, except share and per share data)

(unaudited)

Level 2—Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

Level 3—Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Cash and Cash Equivalents

The Company considers all ~~highly liquid~~highly-liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.

~~The following amounts were presented as cash, cash equivalents and restricted cash:~~


	Nine months ended				Nine months ended				Three months ended				Three months ended
	September 30, 2019				September 30, 2018				March 31, 2020				March 31, 2019
	Beginning		End		Beginning		End		Beginning		End		Beginning		End
	of period		of period		of period		of period		of period		of period		of period		of period
Cash and cash equivalents	$	59,634	$	58,196	$	26,591	$	61,604	$	62,351	$	60,450	$	59,634	$	137,279
Restricted cash included in other assets, noncurrent		371		321		371		371		321		321		371		371
Total cash, cash equivalents and restricted cash per statement of cash flows	$	60,005	$	58,517	$	26,962	$	61,975	$	62,672	$	60,771	$	60,005	$	137,650

Marketable Securities

Short-term marketable securities consist of investments in debt securities with maturities greater than three months and less than one year from the balance sheet date. ~~Long-term marketable securities consist of investments with maturities greater than one year that are not expected to be used to fund current operations.~~ The Company classifies all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Amortization and accretion of discounts and premiums are recorded as interest income within other income. Unrealized gains and losses on available-for-sale ~~debt~~ securities are included in other accumulated comprehensive income (loss) as a component of stockholders’ equity until realized. Realized gains and losses and declines in value judged to be other than temporary are included as a component of other income (expense), net, based on the specific identification method. When determining whether a decline in value is other than temporary, the Company considers various factors, including whether the Company has the intent to sell the security, and whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis. Fair value is determined based on quoted market prices.

Other Assets

The Company recorded other assets of $1,453 as of March 31, 2020 and December 31, 2019, comprised of restricted cash of $321 held as security deposits for a standby letter of credit related to a facility lease and $1,132 held by a service provider.

Net Loss per Share

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without further consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury stock and if-converted methods.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(in thousands, except share and per share data)

(unaudited)

~~Other Assets~~

The Company recorded other assets of $1,453 and $1,503 as of September 30, 2019 and December 31, 2018, respectively, comprised of restricted cash of $321 and $371, respectively, held as security deposits for a standby letter of credit and $1,132 at the end of each period held by a service provider.

~~Net Loss per Share~~

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock and if-converted methods.

For purposes of the diluted net loss per share calculation, ~~convertible preferred~~ stock options, unvested restricted stock units (RSUs) and warrants to purchase common stock and options to purchase common stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be ~~anti-dilutive and therefore,~~anti-dilutive. Therefore, basic and diluted net loss per share were the same for ~~all periods presented.~~the three months ended March 31, 2020.

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the period ended March 31, 2020, because to include them would be anti-dilutive (in common stock equivalent shares):

Three and nine months ended September 30,

2019

2018
Warrants

39,474

110,365
Restricted stock units

447,336

—
Stock options

4,718,597

3,661,962

5,205,407

3,772,327


		Three months ended
		March 31,
		2020
Stock options		6,049,288
Restricted stock units		760,193
Warrants		39,474
		6,848,955

~~Leases~~

~~Consistent with ASC 842,~~For the three months ended March 31, 2019, the Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use lease assets (ROU assets), current portion of lease obligations and long-term lease obligations on the Company’s consolidated balance sheets. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company’s consolidated balance sheets. Lease assets are tested for impairment in the same manner as long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expensereported net income. Diluted earnings per share was computed using the ~~effective interest method.~~"treasury method" by dividing the net income by the weighted-average number of shares of common stock and potentially dilutive securities outstanding during the period. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheets for leases with an original termweighted-average number of ~~twelve months or less.~~

~~ROU assets represent the Company’s right to use an underlying asset~~shares of common stock were adjusted for the ~~lease term, and lease obligations represent the Company’s obligation to make lease payments arising from the lease.~~ Operating lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amountpotential dilutive effect of the ~~lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the~~

~~Table~~exercise of ~~Contents~~

~~Mersana Therapeutics, Inc.~~

~~Notes~~stock options and warrants to ~~condensed consolidated financial statements (continued)~~

~~(in thousands, except share and~~purchase common stock. Refer to Note 7 “Earnings per ~~share data)~~

~~(unaudited)~~

ROU assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.

~~The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.~~share”.

Recently Issued Accounting Pronouncements

~~In February 2016, the FASB issued ASU No. 2016-02,~~ ~~Leases~~ ~~(ASC 842), which replaced the guidance in ASC 840,~~ ~~Leases~~. The updated standard aims to increase transparency and comparability among organizations by requiring lessees to recognize lease assets and lease liabilities on the balance sheet and requiring disclosure of key information about leasing arrangements. This standard is effective for the Company in the fiscal year beginning after December 15, 2018. The Company adopted the new standard effective January 1, 2019 using the modified retrospective method as of the beginning of the period of adoption. The Company has elected the package of practical expedients permitted in ASC Topic 842. Accordingly, the Company accounted for its existing operating leases as operating leases under the new guidance, without reassessing (a) whether the contracts contain a lease under ASC Topic 842, (b) whether classification of the operating leases would be different in accordance with ASC Topic 842, or (c) whether the unamortized initial direct costs would have met the definition of initial direct costs in ASC Topic 842 at lease commencement. The Company also elected not to include leases with an initial term of twelve months or less in the recognized ROU asset and lease liabilities. As a result of the adoption of the new lease accounting guidance, the Company recognized on January 1, 2019 (a) an operating lease liability of $4,778, and (b) an operating ROU asset of $4,369 which represents the lease liability of $4,778 adjusted for deferred rent of $409. This standard had a material impact on the Company’s balance sheets but had no impact on the Company’s results of operations and cash flows from operations. The most significant impact was the recognition of ROU assets and lease obligations for operating leases.

~~In June 2018, the FASB issued ASU No. 2018-07,~~ ~~Improvements to Nonemployee Share-Based Payment Accounting~~. This guidance simplifies the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. This guidance is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, and early adoption is permitted. The guidance per ASU 2018-07 is to be adopted by using a modified retrospective approach with the cumulative effect of initially applying the new standard at the date of initial application. The Company adopted the new standard effective January 1, 2019. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808):Clarifying the Interaction between Topic 808 and Topic 606. The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. This guidance ~~will be~~is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The guidance per ASU 2018-18 is to be adopted retrospectively to the date of initial application of Topic 606. The Company ~~is currently evaluating~~adopted the ~~potential~~new standard effective January 1, 2020. The adoption of this standard did not have a material impact ~~that ASU No. 2018-18 may have~~ on ~~its~~the Company’s consolidated financial ~~position~~statements and ~~results of operations.~~related disclosures.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. Currently, U.S. GAAP delays recognition of the full amount of credit losses until the loss is probable of occurring. Under this ASU, the income statement will reflect an entity’s current estimate of all expected credit losses. The measurement of expected credit losses will be based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down of the security. This ASU is effective for annual periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company adopted the new standard effective January 1, 2020 using the modified retrospective method. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.

1211

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(in thousands, except share and per share data)

(unaudited)

interim periods within those annual reporting periods, and early adoption is permitted. The Company is currently evaluating the potential impact that ASU 2016-13 may have on its financial position and results of operations.

3. Collaboration agreements

Merck KGaA

In June 2014, the Company entered into a Collaboration and Commercial License Agreement with Merck KGaA (the Merck KGaA Agreement). Upon the execution of the agreement, Merck KGaA paid the Company a nonrefundable technology access fee of $12,000 for the right to develop ADCs directed to six exclusive targets over a specified period of time. No additional fees are due when a target is designated and the commercial license to the target is granted. Merck KGaA will be responsible for the product development and marketing of any products resulting from this collaboration. All six targets were designated prior to 2018. The Company is eligible to receive milestones under the Merck KGaA Agreement. The next potential milestone payment is a development milestone of $500 on Merck KGaA’s designation of a preclinical development candidate for any target. Revenue for the milestone is fully constrained until it is certain the milestone would be achieved.

Under the terms of the Merck KGaA Agreement, the Company and Merck KGaA develop research plans to evaluate Merck KGaA's antibodies as ADCs incorporating the Company's technology. The Company receives ~~fees~~reimbursement for its efforts under the research plans. The goal of the research plans is to provide Merck KGaA with sufficient information to formally nominate a development candidate and begin IND-enabling studies or cease development on the designated target.

In May 2018, the Company entered into a Supply Agreement with Merck KGaA (the Merck KGaA Supply Agreement). Under the terms of the ~~agreement,~~Merck KGaA Supply Agreement, the Company will provide Merck KGaA ~~with materials that could be used for IND-enabling studies~~preclinical non-GMP ADC Drug Substance and clinical ~~trials.~~GMP Drug Substance for use in clinical trials associated with one of the antibodies designated under the Merck KGaA Agreement. The Company receives fees ~~and reimbursement~~ for its efforts under the Merck KGaA Supply Agreement and reimbursement equal to the supply cost. The Company may also enter into future supply agreements to provide clinical supply material should Merck KGaA pursue clinical development of any other candidates nominated under the Merck KGaA Agreement.

Accounting Analysis

The Company identified the following performance obligations under the Merck KGaA agreement: (i) exclusive license and research services for six designated targets, (ii) rights to future technological improvements and (iii) participation of project team leaders and providing joint research committee services.

The Company ~~recognizes~~is recognizing revenue related to the exclusive license and ~~the~~ research and development services over the estimated period of the research and development services using a proportional performance model. The Company measures proportional performance based on the costs incurred relative to the total costs expected to be ~~incurred as the Company will satisfy the performance obligations as the research and development services are performed.~~incurred. To the extent that the Company receives fees for the research ~~and development~~ services as they are performed, these amounts are recorded as deferred revenue. Revenue related to future technological improvements and joint research committee services will be recognized ratably over the respective performance ~~periods~~period (which in the case of the joint research committee services approximates the time and cost incurred each ~~quarter)~~period), which are 10 and five years, respectively. The Company ~~continues~~is continuing to reassess the estimated remaining term at each subsequent reporting period. As of December 31, 2018, the total transaction price for the Merck KGaA Agreement was $22,070, which represents the amount of consideration the Company is expected to receive for the transfer of goods and services to Merck KGaA. For each of the three and nine months ended September 30, 2019, the Company decreased the fees expected to be received for research and development activities by $570 ~~to $6,500, resulting in a revised total transaction price for the Merck KGaA Agreement of~~ ~~$21,500 as of September 30, 2019.~~

For the three months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018 and the nine months ended September 30, 2019 and 2018,~~ the Company recorded collaboration revenue of ~~$800, $1,482, $836~~$11 and ~~$2,426,~~$18, respectively, related to its efforts under the Merck KGaA Agreement. During the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019, the Company recognized $0 and $1,037, respectively, in collaboration revenue and corresponding research and development expense related to the Merck KGaA Supply Agreement.

As of March 31, 2020 and December 31, 2019, the Company had $4,804 and $4,815, respectively, in deferred revenue related to the Merck KGaA Agreement and Merck KGaA Supply Agreement that will be recognized over the remaining performance period.

1312

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(in thousands, except share and per share data)

(unaudited)

collaboration revenue and corresponding research and development expense of $34 and $1,255, respectively, related to the Merck KGaA Supply Agreement. Included in accounts receivable as of September 30, 2019 and December 31, 2018 were $262 and $450, respectively, related to the Merck KGaA Supply Agreement.

As of September 30, 2019, the Company had $4,646 in deferred revenue related to the Merck KGaA Agreement and Merck KGaA Supply Agreement that will be recognized in accordance with the proportional performance method.

Takeda XMT-1522 Strategic Partnership

In January 2016, the Company entered into a Development Collaboration and Commercial License Agreement with ~~Takeda through its~~Takeda’s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. for the development and commercialization of XMT-1522 (the XMT-1522 Agreement). Under the XMT-1522 Agreement, Takeda was granted the exclusive right to commercialize XMT-1522 outside of the United States and Canada. Under the XMT-1522 Agreement, the Company was responsible for conducting certain Phase 1 development activities for XMT-1522, including the ongoing Phase 1 clinical trial, at its own expense. The parties agreed to collaborate on the further development of XMT-1522 in accordance with a global development plan (Post-Phase 1 Development). On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate the XMT-1522 Agreement upon 30 days’ prior written notice. The XMT-1522 Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the XMT-1522 Agreement as of March 31, 2019.

Under the XMT-1522 Agreement, the Company and Takeda shared equally all Post-Phase 1 Development costs through the date of termination and for a period of 30 days after the effective termination date.

For the applicable period within the three months ended March 31, 2019, the Company was billed $200 by Takeda, representing the Company’s share of Post-Phase 1 Development costs incurred by Takeda. This amount has been reflected as research and development costs in the consolidated statement of operations.

Takeda strategic research and development partnership

In March 2014, the Company entered into a Research Collaboration and Commercial License Agreement with Takeda through Takeda’s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (the 2014 Agreement). The 2014 Agreement was amended in January 2015 and amended and restated in January 2016 (the 2016 Restated Agreement). The agreements provided Takeda with the right to develop ADCs directed to a total of seven exclusive targets, designated by Takeda, over a specified period of time. On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate the 2016 Restated Agreement upon 45 days’ prior written notice. The 2016 Restated Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the 2016 Restated Agreement as of March 31, 2019.

During the applicable period within the three months ended March 31, 2019, the Company billed Takeda $195 related to ASC 808 costs.

Accounting Analysis

The Company’s collaboration agreements with Takeda were terminated following receipt of written notices during the first quarter of 2019. As there are no further performance obligations, the Company ~~concluded that~~recognized the remaining deferred revenue of $39,965 related to the termination of the ~~XMT-1522 Agreement and the 2016 Restated Agreement resulted~~Takeda agreements in the ~~completion~~first quarter of all of its remaining performance obligations. As a result, $39,965 of previously deferred revenue related to the Takeda agreements as of December 31, 2018 was recognized as revenue during the three months ended March 31, 2019. ~~The Company did not recognize any revenue related to the XMT-1522 Agreement or the 2016 Restated Agreement in the second quarter and will not have any further revenue related to these agreements.~~

~~Included in accounts receivable as of September 30, 2019 and December 31, 2018 was $26 and $9, respectively, related to the Takeda agreements.~~ Included in accounts payable as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018~~2019 was ~~$2,754 and $2,749, respectively,~~$2,335 related to the Takeda agreements.

1413

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(in thousands, except share and per share data)

(unaudited)

Summary of Contract Assets and Liabilities

The following table presents changes in the balances of our contract assets and liabilities during the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 and ~~2018:~~2019:


	Balance at								Balance at
	Beginning						Balance at		Beginning						Balance at
	of Period		Additions		Deductions		End of Period		of Period		Additions		Deductions		End of Period
Nine months ended September 30, 2019
Three months ended March 31, 2020
Contract assets	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—
Contract liabilities:
Deferred revenue	$	46,196	$	—	$	41,550	$	4,646	$	4,815	$	—	$	11	$	4,804

	Balance at								Balance at
	Beginning						Balance at		Beginning						Balance at
	of Period		Additions		Deductions		End of Period		of Period		Additions		Deductions		End of Period
Nine months ended September 30, 2018
Three months ended March 31, 2019
Contract assets	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—
Contract liabilities:
Deferred revenue	$	52,439	$	2,373	$	7,906	$	46,906	$	46,196	$	—	$	40,592	$	5,604

During the three months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018 and the nine months ended September 30, 2019 and 2018,~~ the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods:


	Three months ended				Nine months ended				Three months ended
	September 30,				September 30,				March 31,
	2019		2018		2019		2018		2020		2019
Revenue recognized in the period from:
Amounts included in the contract liability at the beginning of the period	$	834	$	1,760	$	41,550	$	7,515	$	11	$	40,592
Performance obligations satisfied in previous periods	$	—	$	—	$	—	$	—	$	—	$	—

Other Revenue

The Company has provided limited services for a collaboration partner, Asana BioSciences. For the three months ended ~~September 30, 2019~~March 31, 2020 the Company did not recognize any revenue related to these services and ~~2018 and nine~~for the three months ended ~~September 30,~~March 31, 2019, ~~and 2018,~~ the Company recognized ~~revenue~~$15 of ~~$10, $587, $25 and $782, respectively,~~revenue related to these services. In addition, during the nine months ended September 30, 2018, the Company recognized revenue of $1,500 related to a milestone achieved upon the completion of a GLP toxicology study by Asana BioSciences. The Company did not recognize any revenue related to milestones in the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 and 2019. The next potential milestone the Company is eligible to receive is $2,500 upon dosing the fifth patient in a Phase 1 clinical ~~trial~~study by Asana BioSciences. As of ~~September 30, 2019,~~March 31, 2020, the Company considers this next milestone to be fully constrained as there is considerable judgment involved in determining whether it is probable that a significant revenue reversal would occur. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestone is outside the control of the Company and there is a high level of uncertainty in achieving this milestone, as this would require initiation of clinical trials by the collaboration partner. The Company reevaluates the probability of achievement of a milestone subject to constraint at each reporting period and as uncertain events are resolved or other changes in circumstances occur.

1514

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(in thousands, except share and per share data)

(unaudited)

4. Fair value measurements

The following table presents information about the Company's assets and liabilities regularly measured and carried at a fair value and indicates the level within fair value hierarchy of the valuation techniques utilized to determine such value as of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018:~~2019:


					Significant								Significant
			Quoted Prices		Other		Significant				Quoted Prices		Other		Significant
			in Active		Observable		Unobservable				in Active		Observable		Unobservable
	Fair		Markets		Inputs		Inputs		Fair		Markets		Inputs		Inputs
	Value		(Level 1)		(Level 2)		(Level 3)		Value		(Level 1)		(Level 2)		(Level 3)
September 30, 2019
March 31, 2020
Marketable securities:
Commercial paper	$	14,871	$	—	$	14,871	$	—	$	5,983	$	—	$	5,983	$	—
Corporate bonds		12,010		—		12,010		—		11,993		—		11,993		—
U.S. Treasuries		26,925		—		26,925		—
	$	53,806	$	—	$	53,806	$	—	$	17,976	$	—	$	17,976	$	—


					Significant								Significant
			Quoted Prices		Other		Significant				Quoted Prices		Other		Significant
			in Active		Observable		Unobservable				in Active		Observable		Unobservable
	Fair		Markets		Inputs		Inputs		Fair		Markets		Inputs		Inputs
	Value		(Level 1)		(Level 2)		(Level 3)		Value		(Level 1)		(Level 2)		(Level 3)
December 31, 2018
December 31, 2019
Marketable securities:
Commercial paper									$	11,940	$	—	$	11,940	$	—
Corporate bonds										12,010		—		12,010		—
U.S. Treasuries	$	10,497	$	10,497	$	—	$	—		13,489		13,489		—		—
	$	10,497	$	10,497	$	—	$	—	$	37,439	$	13,489	$	23,950	$	—

The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term maturities. There were no changes in valuation techniques or transfers between fair value measurement levels during the nine months ended September 30, 2019 and 2018. As of September 30, 2019, and December 31, 2018, cash and cash equivalents were comprised of cash and money market funds.

There were no changes in valuation techniques or transfers between fair value measurement levels during the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 and ~~2018.~~

~~Cash and Cash Equivalents~~2019.

The carrying amounts ofreflected in the consolidated balance sheets for prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term ~~maturities.~~ nature.

As of ~~September 30, 2019, and December~~March 31, ~~2018, cash and cash equivalents were comprised of cash and money market funds.~~

~~Marketable Securities~~

Marketable securities classified as Level 2 within the valuation hierarchy generally consist of U.S. treasury securities, corporate bonds and commercial paper. The Company estimates the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields and other observable inputs. The Company validates the prices provided by its third-party pricing sources by obtaining market values from other pricing sources and analyzing pricing data in certain instances.~~As of September 30, 2019,~~2020, the carrying value of the Company’s outstanding borrowing under the Credit Facility ~~approximates~~approximated fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company. The Credit Facility is discussed in more detail in Note 7,8, “Debt”.

5. Marketable securities

The following table summarizes marketable securities held at March 31, 2020 and December 31, 2019:


			Gross		Gross
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
March 31, 2020
Commercial paper	$	5,983	$	—	$	—	$	5,983
Corporate bonds		11,997		—		(4)		11,993
	$	17,980	$	—	$	(4)	$	17,976

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(in thousands, except share and per share data)

(unaudited)


			Gross		Gross
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
December 31, 2019
Commercial paper	$	11,940	$	—	$	—	$	11,940
Corporate bonds		11,990		20		—		12,010
U.S. Treasuries		13,484		5		—		13,489
	$	37,414	$	25	$	—	$	37,439

As of March 31, 2020, the Company held three securities that were in an unrealized loss position. The aggregate fair value of securities held by the Company in an unrealized loss position at March 31, 2020 was $8,993. These securities were in a gain position as of December 31, 2019. The Company determined that there was no material change in the credit risk of these securities. The Company does not intend to sell these securities and it is not more likely than not that the Company will be required to sell these securities before recovery of their amortized cost bases, which may be at maturity.

The Company has reviewed securities in an unrealized loss position at the individual security level and evaluated current expected credit loss by considering factors such as the nature of the investments, historical experience, market data, issuer-specific factors, and current economic conditions. During the three months ended March 31, 2020, the Company recognized no year-to-date credit loss related to short term marketable securities, and had no allowance for credit loss recorded as of March 31, 2020.

6. Accrued expenses

Accrued expenses consisted of the following as of March 31, 2020 and December 31, 2019:


	March 31,		December 31,
	2020		2019
Accrued payroll and related expenses	$	1,549	$	4,037
Accrued preclinical, manufacturing and clinical expenses		3,367		4,230
Accrued professional fees		716		675
Accrued other		46		44
	$	5,678	$	8,986

7. Earnings per share

The following table presents the calculation of basic and diluted net income per share:


	Three months ended
	March 31,
		2020		2019
Numerator:
Net income (loss)	$	(16,926)	$	21,901
Denominator:
Weighted-average number of shares - basic		47,988,630		30,299,650
Dilutive securities - share-based awards		—		1,052,730
Dilutive securities - common stock warrants		—		109,316
Weighted-average number of shares - diluted		47,988,630		31,461,696

Net income (loss) per share - basic	$	(0.35)	$	0.72
Net income (loss) per share - diluted	$	(0.35)	$	0.70

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(in thousands, except share and per share data)

(unaudited)

~~5. Marketable~~

Anti-dilutive stock-based awards excluded from the calculation of diluted EPS for the three months ended March 31, 2019 were 2,686,700.

For the three months ended March 31, 2020, potentially dilutive securities were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, therefore basic and diluted net loss per share were the same for the three months ended March 31, 2020.

~~The following table summarizes marketable securities held at September 30, 2019 and December 31, 2018:~~

Gross

Gross

Amortized

Unrealized

Unrealized

Fair


Cost

Gains

Losses

Value
September 30, 2019

Commercial paper

$
14,871

$
—

$
—

$
14,871
Corporate bonds

11,984

26

—

12,010
U.S. Treasuries

26,923

2

—

26,925

$
53,778

$
28

$
—

$
53,806

Gross

Gross

Amortized

Unrealized

Unrealized

Fair


Cost

Gains

Losses

Value
December 31, 2018

U.S. Treasuries

$
10,505

$
—

$
(8)

$
10,497

$
10,505

$
—

$
(8)

$
10,497

~~6. Accrued expenses~~

~~Accrued expenses consisted of the following:~~

September 30,

December 31,

2019

2018
Accrued payroll and related expenses

$
3,080

$
3,042
Accrued preclinical, manufacturing and clinical expenses

4,017

8,314
Accrued professional fees

710

567
Accrued other

230

452

$
8,037

$
12,375

7.8. Debt

On May 8, 2019, the Company entered into a loan and security agreement (the Credit Facility) with Silicon Valley Bank (SVB) pursuant to which the Company can borrow, at its option, up to $20,000, in up to four principal advances of at least $5,000 each (each, a Term Loan or collectively, the Term Loans) through August 31, 2020. The Company drew $5,000 on the Term Loan upon execution of the Credit Facility.

The Term Loans bear interest at a floating per annum rate equal to the greater of (i) 4.0% and (ii) 1.50% below the Prime Rate, as defined. The Company is obligated to make monthly interest only payments on each outstanding Term Loan commencing on the first calendar day of the month following the funding date of such Term Loan and continuing on the first calendar day of each month thereafter through August 31, 2020. Commencing on September 1, 2020 and continuing on the first calendar day of each month thereafter, the Company is obligated to make 30 consecutive equal payments of principal, together with applicable interest in arrears to SVB.

All outstanding principal and accrued and unpaid interest with respect to the Term Loans are due and payable in full on February 1, 2023. Upon repayment of the Term Loans, the Company is also required to make a final payment to SVB equal to 5.0% of the principal amount of the Term Loans then extended to the Company. This final payment is accreted under the effective interest method over the life of each loan. The Term Loans are secured by substantially all of the

~~Table of Contents~~

~~Mersana Therapeutics, Inc.~~

~~Notes to condensed consolidated financial statements (continued)~~

~~(in thousands, except share and per share data)~~

~~(unaudited)~~

~~Company’s assets, except for its intellectual property which is subject to a negative pledge, and certain other customary exclusions.~~

At the Company’s option, it may prepay the outstanding principal balance of any Term Loans in whole but not in part, subject to a prepayment fee of: (a) 3.0% of the Term Loans then extended to the Company if the prepayment occurs on or prior to May 8, 2020, (b) 2.0% of the Term Loans then extended to the Company if the prepayment occurs after May 8, 2020 but on or prior to May 8, 2021, or (c) 1.0% of the Term Loans then extended to the Company if the prepayment occurs after May 8, 2021 but before February 1, 2023. In the event the Company has not borrowed a total of $20,000 upon the earlier of August 21, 2020, acceleration of the Company’s payment obligations or Company’s prepayment of the then extended Term Loans, the Company is required to pay an additional fee equal to 3.0% of any unborrowed portion of the committed funding (the Unused Term Loan Commitment Fee).

The Credit Facility includes customary affirmative, financial, and restrictive covenants applicable to the Company. Affirmative covenants include, among others, covenants requiring the Company to maintain its corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. Financial covenants include maintaining a liquidity ratio (as defined in the Credit Facility) of 1.50 to 1.00. The restrictive covenants include, among others, requirements relating to the Company’s ability to transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other distributions, make investments, create liens, sell assets and agree to a change in control, in each case subject to certain customary exceptions.

The Company’s payment obligations under the Credit Facility are subject to acceleration upon the occurrence of specified events of default, which include, but are not limited to, the occurrence of a material adverse change in the Company’s business, operations, or financial or other condition. Amounts outstanding upon the occurrence of an event of default are payable upon SVB’s demand and shall accrue interest at an additional rate of 5.0% per annum of the past due amount outstanding. As of ~~September 30, 2019,~~March 31, 2020, the Company was in compliance with all covenants under the Credit Facility. As such, as of ~~September 30, 2019,~~March 31, 2020, the classification of the loan balance as stated on the balance sheet was based on the timing of defined future payment obligations.

The Company incurred $215 of debt issuance costs related to external legal and transaction fees. The Company recorded the debt issuance costs as a direct deduction from the carrying value of the Term Loans which are amortized as interest expense using the effective-interest method over the term of the Term Loans.

As of ~~September 30, 2019,~~March 31, 2020, the Company had drawn a Term Loan of $5,000.

As of ~~September 30, 2019, Debt~~March 31, 2020, debt consisted of the following:


	September 30,		March 31,
	2019		2020
Total debt	$	5,000	$	5,000
Less: Current portion of long-term-debt		(167)		(1,167)
Total debt, net of current portion		4,833		3,833
Debt financing costs, net of accretion		(191)		(163)
Accretion related to final payment		28		62
Long-term debt, net	$	4,670	$	3,732

As of March 31, 2020, the estimated future principal payments due are as follows:


2020 (excluding the three months ended March 31, 2020)	$	667
2021		2,000
2022		2,000
2023		333
Total debt	$	5,000

During the three months ended March 31, 2020, the Company recognized $51 of interest expense related to the Credit Facility.

1817

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(in thousands, except share and per share data)

(unaudited)

~~As of September 30, 2019, the estimated future principal payments due are as follows:~~

2019 (excluding the nine months ended September 30, 2019)

$
—
2020

666
2021

2,000
2022

2,000
2023

334
Total debt

$
5,000

~~During the three and nine months ended September 30, 2019, the Company recognized $51 and $64, respectively, of interest expense related to the Credit Facility.~~

8.9. Stockholders’ equity

Preferred stock

As of ~~September 30, 2019,~~March 31, 2020, the Company had 25,000,000 shares of authorized preferred stock. No shares of preferred stock have been issued.

Common stock

The holders of the common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors (the Board).

InAt March 31, 2020 and December 31, 2019, ~~the Company completed a follow-on public offering in which the Company issued~~there were 6,848,955 and ~~sold an aggregate of 24,437,500 shares of its common stock at the public offering price of $4.00 per share, which included the exercise in full of the underwriters’ option to purchase additional~~7,782,582, respectively, shares of common ~~stock. The net proceeds from the offering were $92,162.~~

~~At September 30, 2019 and December 31, 2018, there were 5,205,407 and 3,856,932 shares of common~~ stock ~~respectively,~~ reserved for the exercise of outstanding stock options, restricted stock units and warrants.


	September 30,	December 31,	March 31,	December 31,
	2019	2018	2020	2019
Stock options			6,049,288	4,720,772
Restricted stock units			760,193	447,336
Warrants	39,474	110,365	39,474	39,474
Restricted stock units	447,336	—
Stock options	4,718,597	3,746,567
Exchange warrants			—	2,575,000
	5,205,407	3,856,932	6,848,955	7,782,582

At-the-market equity offering program

On July 2, 2018, the Company established an at-the-market equity offering program (ATM) pursuant to which it is able to offer and sell up to $75,000 of its common stock from time to time at prevailing market prices. As of ~~September 30, 2019,~~March 31, 2020, the Company had not sold any shares under the ATM.

Warrants

In connection with a 2013 Series A-1 Preferred Stock issuance, the Company granted to certain investors warrants to purchase 129,491 shares of common stock. The warrants have a $0.05 per share exercise price and a contractual life of 10 years. The fair value of these warrants was recorded as a component of equity at the time of issuance. As of March 31, 2020, there were warrants to purchase 39,474 shares of common stock.

Exchange Warrants

On November 26, 2019, the Company entered into an exchange agreement with entities affiliated with Biotechnology Value Fund, L.P. (the “Exchanging Stockholders”), pursuant to which the Exchanging Stockholders exchanged an aggregate of 2,575,000 shares of common stock for warrants (the “Exchange Warrants”) to purchase an aggregate of 2,575,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, merger or consolidation, change of control, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.0001 per share.

On March 2, 2020, the Exchanging Stockholders exercised the Exchange Warrants in full on a net cashless exercise basis, resulting in the issuance of 2,574,971 shares of common stock.

1918

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(in thousands, except share and per share data)

(unaudited)

~~September 30, 2019, warrants to purchase 39,474 shares of common stock were outstanding. During the quarter ended September 30, 2019, the Company issued 69,680 shares of common stock upon the exercise of warrants.~~

9.10. Stock options

Stock option plans

In June 2017 the Company’s shareholders approved the 2017 Stock Incentive Plan (the 2017 Plan). Under the 2017 Plan, up to 2,255,000 shares of common stock ~~may~~were initially available to be granted to the Company's employees, officers, directors, consultants and advisors in the form of options, restricted stock ~~awards~~units (RSUs) or other stock-based awards. The ~~2017 Plan provides that the~~ number of shares of common stock issuable under the 2017 Plan ~~shall~~will be cumulatively increased annually by 4% of the outstanding shares or such lesser amount specified by the Board. The terms of the awards are determined by the Board, subject to the provisions of the 2017 Plan. As of the adoption date of the 2017 Plan, there were 3,141,625 options outstanding under the Company’s 2007 Stock Incentive Plan (the 2007 Plan) (the 2007 Plan and the 2017 Plan collectively are referred to as the Plans). Any cancellations under the 2007 Plan, which expired in June 2017, would increase the number of shares that could be granted under the 2017 Plan. In January ~~2019,~~2020, the number of shares of common stock issuable under the 2017 Plan was increased by ~~929,378~~1,815,520 shares. As of ~~September 30, 2019,~~March 31, 2020, there were ~~1,983,432~~1,642,679 shares available for future issuance under the 2017 Plan.

With respect to incentive stock options, the ~~option~~exercise price per share will equal the fair market value of the common stock on the date of grant, ~~which is generally the closing price for a share of the Company’s common stock on the Nasdaq Global Select Market on such date,~~ and the vesting period is generally four years. Nonqualified stock options will be granted at an exercise price established by the Board at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Options granted under the 2017 Plan expire no later than 10 years from the date of grant. The Board may accelerate vesting or extend the expiration of granted options in the case of a merger, consolidation, dissolution, or liquidation of the Company.

Stock option activity

A summary of the options activity under the Plans is as follows:


		Weighted-			Weighted-
	Number	Average		Number	Average
	of Shares	Exercise Price		of Shares	Exercise Price

Options outstanding at January 1, 2019	3,746,567	$	6.58
Outstanding at January 1, 2020				4,720,772	$	5.24
Granted	1,630,283		3.74	1,412,653		6.10
Exercised	(58,964)		2.04	(43,055)		2.77
Cancelled	(599,289)		9.42	(41,082)		8.50
Options outstanding at September 30, 2019	4,718,597	$	5.29
Outstanding at March 31, 2020				6,049,288	$	5.44

Options exercisable at September 30, 2019	2,531,612	$	4.36

Exercisable at March 31, 2020				2,846,100	$	4.68

The weighted-average grant date fair value of options granted during the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018,~~ was $~~2.47~~3.79 and $~~9.45~~2.39 per share, respectively.

Cash received from the exercise of stock options was ~~$121~~$119 and $~~853~~42 for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018,~~ respectively.

Restricted stock units

In July 2019, the Company issued ~~449,331 restricted stock units~~RSUs with service conditions to employees. The awards cliff-vest two years after the grant date. In January 2020, the Company issued 324,932 RSUs with a service condition to employees offor which ~~447,366 are outstanding as of September 30, 2019. Vesting of these awards is contingent on~~ the ~~fulfillment of the service~~

2019

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(in thousands, except share and per share data)

(unaudited)

~~conditions. The weighted-average grant date fair value~~vesting term is annually over four years. Vesting of ~~restricted stock units was $4.00 per share. The Company recognized $184 of expense related to~~ these awards inis contingent on the ~~third quarter~~fulfillment of ~~2019 and will continue to recognize stock-based compensation expense related to these awards through July 2021 when~~ the ~~awards vest.~~service conditions during the vesting term.

A summary of the RSU activity under the 2017 Plan is as follows:


		Number
		of Shares

Unvested at January 1, 2020		447,336
Granted		324,932
Vested		—
Forfeited		(12,075)
Unvested at March 31, 2020		760,193

Stock-based compensation expense

The Company uses the provisions of ASC 718, Stock Compensation, to account for all stock-based awards to employees and nonemployees.

The measurement date for employee awards is generally the date of grant. Stock-based compensation expense is recognized over the requisite service period, which is generally the vesting period, using the straight-line method.

The following table presents stock-based compensation expense by award type included within the Company’s condensed consolidated statement of operations and comprehensive loss:


	Three months ended				Nine months ended				Three months ended
	September 30,				September 30,				March 31,
		2019		2018		2019		2018		2020		2019
Stock options	$	1,055	$	988	$	3,240	$	2,692	$	1,233	$	1,094
Restricted stock units		184		—		184		—		310		—
Employee stock purchase plan		46		65		186		65		66		70
Stock-based compensation expense included in Total operating expenses	$	1,285	$	1,053	$	3,610	$	2,757	$	1,609	$	1,164

The following table presents stock-based compensation expense as reflected in the Company’s condensed consolidated statements of operations and comprehensive loss:


	Three months ended				Nine months ended				Three months ended
	September 30,				September 30,				March 31,
		2019		2018		2019		2018		2020		2019
Research and development	$	587	$	495	$	1,636	$	1,302	$	797	$	516
General and administrative		698		558		1,974		1,455		812		648
Stock-based compensation expense included in Total operating expenses	$	1,285	$	1,053	$	3,610	$	2,757	$	1,609	$	1,164

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(in thousands, except share and per share data)

(unaudited)

~~The Company had an aggregate~~As of March 31, 2020, there was $~~8,290~~11,341 and $3,022 of unrecognized stock compensation ~~cost as of September 30, 2019 remaining~~expense related to unvested stock options and unvested RSUs, respectively, that is expected to be ~~amortized~~recognized over ~~the~~a weighted-average period of ~~2.2~~2.5 and 2.9 years.~~As of September 30, 2019, the Company had $1,605 of unrecognized stock-based compensation expense related to restricted stock units.~~

The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:


	Three months ended				Nine months ended				Three months ended
	September 30,				September 30,				March 31,
	2019		2018		2019		2018		2020		2019
Risk-free interest rate	1.9	%	2.9	%	2.4	%	2.7	%	1.6	%	2.6	%
Expected dividend yield	—	%	—	%	—	%	—	%	—	%	—	%
Expected term (years)	6.11		5.85		5.99		6.06		6.04		6.00
Expected stock price volatility	75	%	73	%	74	%	73	%	69	%	74	%

Employee Stock Purchase Plan

During the year ended December 31, 2017, the Board adopted and the Company’s stockholders approved the 2017 employee stock purchase plan (the 2017 ESPP). The Company initially reserved 225,000 shares of common stock for issuance under the 2017 ESPP. In January ~~2019,~~2020, the number of shares of common stock for issuance under the 2017 ESPP was increased by 450,000 shares. The Company did not issue any shares under the 2017 ESPP during the three months ended March 31, 2020 and 2019. As of March 31, 2020, there were 725,085 shares available for issuance under the 2017 ESPP.

11. Leases

The Company has an operating lease for its office space in Cambridge, MA and operating and finance leases for certain equipment. In March 2020, the Company entered into the Seventh Amendment to the office space lease to extend the term of the lease through March 2026 and to provide the Company with a tenant improvement allowance of $172. The current rate per square foot that is in place through March 2021 (the original expiration date of the lease) did not change. After March 2021, there are predetermined fixed escalations of the rate as outlined in the amendment. The Company has an option to extend the lease term for an additional five years. The Company’s exercise of this option was not considered reasonably certain as of March 31, 2020.

The extension is accounted for as a lease modification. The Company assessed the lease classification of the amended office space lease at the modification date and determined that the amended office space lease should be accounted for as an operating lease. The right-of-use asset and corresponding operating lease liability have been remeasured based on the present value of remaining lease payments over the remaining extended lease term, using the incremental borrowing rate applicable as of the lease modification date. The Company determined the appropriate incremental borrowing rate by using a synthetic credit rating which was estimated based on an analysis of outstanding debt of companies with similar credit and financial profiles. Since the operating lease is a net lease, as the non-lease components (i.e., common area maintenance) are paid separately from rent based on actual costs incurred, such non-lease components were not included in the right-of-use asset and liability and are reflected as an expense in the period incurred.

As a result of the modification, the Company recorded an increase of $9,980 to its right-of-use (ROU) asset and lease liabilities.

Table of Contents

Mersana Therapeutics, Inc.

Notes to condensed consolidated financial statements (continued)

(in thousands, except share and per share data)

(unaudited)

~~ESPP was increased by 232,344 shares. The Company did not issue any shares under~~

Following the ~~2017 ESPP during~~change, the three months ended September 30, 2019. During the nine months ended September 30, 2019, the Company issued 82,281 shares under the 2017 ESPP. The Company did not issue any shares under the 2017 ESPP during the three and nine months ended September 30, 2018 As of September 30, 2019, there were 332,877 shares available for issuance under the 2017 ESPP.

~~10. Leases~~

The Company has an operating lease for its facility and operating and finance leases for certain equipment. The Company leases office space in Cambridge, MA under an operating lease, which was last amended in January 2018, and is effective through March 2021. The Company has an option to extend the lease term for an additional five years. The Company’s exercise of this option was not considered reasonably certain as of September 30, 2019. The Company has remaining lease terms of three years to five years for certain equipment, some of which may include options to purchase at fair value.

~~During the first quarter of 2019, the Company entered into finance leases for certain equipment. The Company recorded assets under finance leases of $429 as property and equipment.~~

~~Table of Contents~~

~~Mersana Therapeutics, Inc.~~

~~Notes to condensed consolidated financial statements (continued)~~

~~(in thousands, except share and per share data)~~

~~(unaudited)~~

~~The components of lease expense were as follows:~~

Three months ended

Nine months ended

September 30, 2019
Operating lease cost

$
540

$
1,620

Finance lease cost:

Amortization of right-of-use assets

$
25

$
50
Interest on lease liabilities

7

14

$
32

$
64

~~Supplemental balance sheet information related to leases was as follows:~~

Nine months ended

September 30, 2019
Operating leases:

Operating lease right-of-use assets

$
3,059
Operating lease liabilities, current

2,145
Operating lease liabilities

1,257

Finance leases:

Property and equipment, gross

$
429
Property and equipment, accumulated depreciation

(50)
Other liabilities, current

85
Other liabilities

299

Weighted-average remaining lease term:

Operating leases

1.6 years
Finance leases

4.0 years

Weighted-average discount rate:

Operating leases

10.3%
Finance leases

6.9%

~~Table of Contents~~

~~Mersana Therapeutics, Inc.~~

~~Notes to condensed consolidated financial statements (continued)~~

~~(in thousands, except share and per share data)~~

~~(unaudited)~~

~~Supplemental cash flow information related to leases was as follows:~~

Nine months ended

September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows from operating leases

$
1,685
Operating cash flows from finance leases

14
Financing cash flows from finance leases

58
Right-of-use assets obtained in exchange for lease obligations:

Operating leases

4,369
Finance leases

429

~~Future~~future minimum lease payments under non-cancellable leases as of ~~September 30, 2019~~March 31, 2020 were as follows:

Operating leases

Finance leases
2019 (excluding the nine months ended September 30, 2019)

$
586

$
29
2020

2,394

116
2021

687

116
2022

—

84
2023 and thereafter

—

92

3,667

437
Imputed interest

—

(8)

$
3,667

$
429


	Operating leases		Finance leases
2020 (excluding the three months ended March 31, 2020)	$	1,809	$	87
2021		2,772		116
2022		2,843		84
2023		2,928		74
2024 and thereafter		6,904		18
Total lease payments		17,256		379
Present value adjustment		(4,811)		(41)
Present value of lease liabilities	$	12,445	$	338

1112. Commitments

License agreements

Through ~~September 30, 2019,~~March 31, 2020, the Company had licensed intellectual property from two biotechnology companies. The consideration included upfront payments and a commitment to pay annual license fees, milestone payments and, upon product commercialization, royalties on revenue generated from the sale of products covered by the licenses. The Company ~~recorded a milestone payment of $600 during the three and nine months ended September 30, 2019 upon dosing of the first patient in the expansion cohort of the XMT-1536 clinical trial. The Company~~ did not record any milestone payments during the ~~nine~~three months ended ~~September 30, 2018.~~March 31, 2020 and 2019.

13. Subsequent Events

~~12. Subsequent events~~

~~For the purposes of the unaudited financial statements as of September 30, 2019 and the period then ended,~~On July 2, 2018, the Company ~~has evaluated subsequent events~~established an at-the-market equity offering program (ATM) pursuant to which it is able to offer and sell up to $75,000 of its common stock from time to time at prevailing market prices. As of March 31, 2020, the Company had not sold any shares under the ATM. On April 7, 2020, the Company sold 8,938,599 and 1,962,000 shares of common stock at$5.59 per share and $7.74 per share, respectively, to raise gross proceeds of $65,153 through ~~November 6, 2019, the date the unaudited interim financial statements were issued. There were no items requiring adjustment or disclosure in the consolidated financial statements.~~this ATM facility.

2422

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the accompanying notes ~~thereto~~ appearing elsewhere in this Quarterly Report on Form 10-Q and the audited financial ~~information~~statements and the accompanying notes ~~thereto~~ included in our Annual Report on Form 10-K for the year ended December 31, ~~2018~~2019 filed with the Securities and Exchange Commission (SEC) on ~~March 8, 2019.~~February 28, 2020.

Our actual results and the timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly ~~Report on Form 10-Q.~~Report. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report, ~~on Form 10-Q,~~ they may not be predictive of results or developments in future periods.

The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report on Form 10-Q, ~~and~~including those risks identified under Part II, Item 1A. Risk Factors, and in our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, filed with the SEC on ~~March 8, 2019.~~February 28, 2020, including those risks identified under Item 1A. Risk Factors.

We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Overview

We are a ~~clinical stage~~clinical-stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need. We have leveraged ~~over~~ 20 years of industry learning in the ADC field to develop proprietary ~~technologies~~and differentiated technology platforms that enable us to design ADCs to have improved efficacy, safety and tolerability relative to existing ADC therapies.

We believe that our innovative platforms which include Dolaflexin and Dolasynthen, each delivering our DolaLock payload, as well as Immunosynthen, delivering a novel stimulator of interferon genes, or STING, agonist, provide a highly efficient product engine that has enabled a robust discovery pipeline for us and our partners. Our ~~novel platform, Dolaflexin, has been used~~ADCs in preclinical and clinical studies are first-in-class molecules that target multiple tumor types with high unmet medical need and have exhibited improved safety and efficacy compared to ~~generate~~ADCs developed using first-generation technology.

Our goal is to become a ~~pipeline~~leading oncology company by leveraging the potential of ~~proprietary~~our innovative and differentiated ADC technologies, and the experience and competencies of our management team to identify, acquire and develop promising ADC product candidates and to ~~address patient populations~~commercialize cancer therapeutics that are ~~not currently amenable to treatment with traditional ADC-based therapies.~~ ~~Our lead~~ ~~product candidate,~~ improvements over existing treatments.

XMT-1536, is a first-in-class ~~wholly-owned Dolaflexin~~ ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver an average of 10 to 12 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in NSCLC adenocarcinoma and ovarian cancer with limited expression in normal tissue. We are actively recruiting and dosing patients with ovarian cancer and ~~non-small cell lung cancer (NSCLC) adenocarcinoma.~~ ~~In August 2019, we announced~~NSCLC adenocarcinoma, where a majority of patients express NaPi2b in a Phase 1 clinical trial.

We have also selected our next clinical product candidate, XMT-1592. XMT-1592 uses one of our new platforms, Dolasynthen, and also targets NaPi2b. XMT-1592 comprises the ~~dosing~~same proprietary NaPi2b antibody and potent auristatin DolaLock payload with controlled bystander effect as XMT-1536, with the additional features of homogeneous, site-specific bioconjugation and precise drug-to-antibody ratio, or DAR. We filed an Investigational New Drug (IND) application in the first ~~patient in~~quarter of 2020, which was approved by the ~~expansion portion of~~U.S. Food and Drug Administration (FDA). We remain on track to initiate the Phase ~~1 study of XMT-1536. The expansion cohorts will assess the efficacy, safety and tolerability of XMT-1536 at 36 mg/m~~2 every four weeks in patients with platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. We have not yet determined a maximum tolerated dose, and we plan to continue the dose escalation portion of the study in parallel.

In June 2019, we presented interim efficacy and safety data from the ongoing Phase 1 dose-escalation study evaluating XMT-1536 at the American Society of Clinical Oncology (ASCO) Annual Meeting in a poster titled “Phase 1 dose escalation study of ~~XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.” We continue to add sites to support the expansion cohorts initiated~~XMT-1592 in the ~~third~~second quarter of ~~2019. By evaluating~~2020.

Table of Contents

Our early stage programs include a potentially first-in-class B7-H4-targeted DolaLock ADC addressing areas of high unmet medical need. Our objective is to rapidly progress through IND-enabling studies and scale up manufacturing activities with third parties. B7-H4 provides significant opportunities for development in areas of high unmet need such as breast cancer, NSCLC and ovarian cancer.

In addition, we have established strategic research and development partnerships with Merck KGaA and Asana Biosciences for the ~~expansion cohorts, we aim~~development and commercialization of additional ADC product candidates against a limited number of targets selected by our partners based on our Fleximer platform. We believe the potential of our ADC technologies, supported by our world class management team and protected by our robust intellectual property portfolio, will allow us to ~~establish proof of concept in platinum-resistant ovarian~~develop targeted and highly tailored therapies to help cancer ~~and NSCLC adenocarcinoma.~~patients become cancer survivors.

Since inception, our operations have focused on building our platforms, identifying potential product candidates, producing drug substance and drug product material for use in preclinical studies, conducting preclinical and toxicology studies, manufacturing clinical ~~trial~~study material and conducting clinical ~~trials,~~studies, establishing and protecting our intellectual property, staffing our company and raising capital. We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations primarily through our strategic partnerships, private placements of our convertible preferred stock and public offerings of our common stock.On April 7, 2020, we sold 8.9 million and 2.0 million shares of common stock at $5.59 per share and $7.74 per share, respectively, to raise gross proceeds of approximately $65 million through our at-the-market equity offering program, or ATM.

Since inception, we have incurred significant cumulative operating losses. For the ~~nine~~three months ended ~~September 30, 2019,~~March 31, 2020, the net loss was ~~$12.0~~$16.9 million, compared to ~~$41.8~~net income of $21.9 million in the ~~nine~~three months ended ~~September 30, 2018.~~March 31, 2019. The

~~Table of Contents~~

difference year over year is primarily attributable to $40.0 million in revenue that was recognized in the first quarter of 2019 as a result of the discontinuation of the partnership with Takeda in that quarter. ~~Cash used in operations for the three and nine months ended September 30, 2019 was $16.3 million and $55.2 million, respectively.~~ As of ~~September 30, 2019,~~March 31, 2020, we had an accumulated deficit of ~~$176.1~~$209.3 million. We expect to continue to incur significant expenses and operating losses over the next several years. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:

continue clinical development activities for our lead product candidate ~~XMT-1536;~~ XMT-1536 and initiate clinical development activities for XMT-1592;

develop a research assay and companion diagnostic for the NaPi2b biomarker;

continue activities to discover, validate and develop additional product candidates;

maintain, expand and protect our intellectual property portfolio; and

hire additional research, development and general and administrative personnel.

Impact of COVID-19 on Our Business

The coronavirus pandemic continues to evolve rapidly. We are monitoring the impact of the COVID-19 pandemic on operations and ongoing clinical and preclinical development, as well as discovery efforts. Mitigation activities to minimize COVID-19-related operation disruptions are ongoing and include:

In line with guidance from the U.S. Centers for Disease Control and Prevention (CDC) and the state of Massachusetts, we have implemented work from home measures for all non-laboratory employees and have suspended all business travel. We have also prioritized laboratory activities and implemented staggered schedules in the interest of safety and efficiency for any laboratory-based employees.

We are currently working with over 20 investigational sites in different geographic areas across the United States which are enrolling patients in the XMT-1536 Phase 1 study. Consistent with FDA guidance, we issued an administrative letter to allow for remote patient monitoring and remote testing, when possible. Most of the study sites continue to enroll patients in the study. At this time and subject to further COVID-19 implications to patient enrollment, we expect to be able to present more mature data from the expansion portion of the study in the second half of 2020.

Table of Contents

We believe we have sufficient inventory of XMT-1536 and XMT-1592 to support our ongoing and planned clinical studies as well as sufficient inventory of advanced intermediates stockpiled in the United States to support more than two years of manufacturing of drug substance and product. At this time and subject to further COVID-19 implications, we do not anticipate any disruptions to its clinical supply.

The ultimate impact of the coronavirus pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted. While the pandemic did not materially affect our financial results and business operations in the first quarter ended March 31, 2020, we are unable to predict the impact that COVID-19 will have on our financial position and operating results in future periods due to numerous uncertainties. Management is actively monitoring this situation and the possible effects on our financial condition, operations, suppliers, industry, and our employees. For additional information about risks and uncertainties related to the COVID-19 pandemic that may impact our business, our financial condition or our results of operations, see “Part II, Item 1A—Risk Factors” below in this Form 10-Q.

Financial operations overview

Revenue

To date, we have not generated any revenue from the sale of products. All of our revenue has been generated from strategic partnerships.

In June 2014, we entered into an agreement with Merck KGaA for the development and commercialization of ADC product candidates utilizing ~~our~~ Fleximer ~~polymer scaffold~~ for up to six target antigens. Merck KGaA is responsible for generating antibodies against the target antigens and we are responsible for generating Fleximer and our proprietary payloads and conjugating this to the antibody to create the ADC product candidates. Merck KGaA has the exclusive right to and is responsible for the further development and commercialization of these ADC product candidates. In May 2018, we entered into a supply agreement with Merck KGaA for the supply of materials that could be used for ~~Investigational New Drug-enabling~~IND-enabling studies and clinical trials.

For the three months ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018 and the nine months ended September 30, 2019 and 2018,~~ we recognized revenue of ~~$0.8 million, $1.5 million, $2.1 million~~an immaterial amount and ~~$2.4~~$1.0 million, respectively, related to ~~our license agreement and supply agreement with~~the Merck ~~KGaA.~~KGaA agreements.

In January 2016, we entered into ~~an agreement~~collaboration agreements with Takeda for the development and commercialization of XMT-1522, a HER2-targeted ~~ADC. Under this agreement, Takeda was granted the exclusive right~~ADC, and ~~responsibility~~up to ~~commercialize XMT-1522 outside the United States and Canada.In addition, in January 2016, we entered into an agreement with Takeda for the development and commercialization of~~seven ADC product candidates utilizing Fleximer.

In January 2019, following a strategic evaluation by the Company of the competitive environment for HER2-targeted therapies, the Company and Takeda decided to discontinue the development of XMT-1522, which was then being studied in the dose escalation of a Phase 1 clinical trial. The Company’s collaboration agreements with Takeda were terminated ~~following receipt of written notices~~ during the first quarter of 2019.

We recognized the remaining deferred revenue of $40.0 million related to the termination of the Takeda agreements in the first quarter of 2019. We ~~did not recognize any revenue related to the Takeda agreements in the second or third quarter and~~ do not expect to have any further revenue related to these agreements.

We have provided limited services ~~for~~to Asana BioSciences. WeFor each of the three months ended March 31, 2020 and 2019, we recorded an immaterial amount of revenue ~~for these services in the three and nine months ended September 30, 2019. For the three and nine months ended September 30, 2018, we recorded revenue of $0.6 million and $0.8 million, respectively,~~ related to these services. ~~In addition, the Company recognized revenue of $1.5 million related to a milestone achieved during the nine months ended September 30, 2018.~~ The Company did not recognize any revenue related to milestones in the three ~~and nine~~ months ended ~~September 30,~~March 31, 2020 or 2019.

~~Table of Contents~~

For the foreseeable future, we expect substantially all of our revenue to be generated from our collaboration agreements with Merck KGaA and Asana BioSciences. Given the uncertain nature and timing of clinical development, we cannot predict when or whether we will receive further milestone payments or any royalty payments under these collaborations.

Operating expenses

Research and development expenses

Research and development expenses consist primarily of costs incurred for our research and development activities, including our drug discovery efforts, and the development of our product candidates, which include:

employee-related expenses, including salaries, ~~bonus,~~bonuses, benefits and stock-based compensation expense;

costs of funding research and development performed by third parties that conduct research, preclinical activities, manufacturing and clinical trials on our behalf;

Table of Contents

laboratory supplies;

facility costs, including rent, depreciation and maintenance expenses; and

upfront and milestone payments under our third-party licensing agreements.

Research and development costs are expensed as incurred. Costs of certain activities, such as manufacturing and preclinical ~~studies~~ and clinical ~~trials,~~studies, are generally recognized based on an evaluation of the progress to completion of specific tasks. ~~Nonrefundable advance payments~~Costs for ~~goods or services~~certain development activities, such as clinical studies, are recognized based on an evaluation of the progress to ~~be received in~~completion of specific tasks using data such as patient enrollment, clinical site activations and information provided to us by the ~~future for use in research~~third parties with whom we contract.

Research and development activities are ~~deferred~~central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and ~~capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.~~

duration of later-stage clinical trials and manufacturing costs. We expect that our total future research and development costs will continue to increase ~~significantly for~~over current levels, depending on the ~~foreseeable future as~~progress of our ~~product candidate~~clinical development ~~programs progress.~~programs. There are numerous factors associated with the successful development and commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at our current stage of development. Additionally, future commercial and regulatory factors beyond our control may impact our clinical development programs and plans.

A significant portion of our research and development costs have been external costs, which we track on a program-by-program basis following nomination as a product candidate. We have not historically tracked all of our internal research and development expenses on a program-by-program basis as they are deployed across multiple projects under development. The following table summarizes our external research and development expenses, by program, following nomination as a development ~~candidate.~~candidate for the three months ended March 31, 2020 and 2019. All external research and development expenses not attributable to the XMT-1536, XMT-1592 and XMT-1522 programs are captured within preclinical and discovery costs. These costs relate to XMT-1592 prior to its designation as our next ADC clinical candidate, as well as additional earlier discovery stage programs and certain unallocated costs. We terminated the development of XMT-1522 in the first quarter of 2019. Our internal research and development costs are primarily personnel-related costs, stock-based compensation costs, and facility costs, including depreciation and lab consumables. Pre-development candidate expenses, unallocated costs and internal research and development costs have been stated separately.


	Three months ended				Nine months ended				Three months ended
	September 30,				September 30,				March 31,
(in thousands)	2019		2018		2019		2018		2020		2019
XMT-1536 external costs	$	2,193	$	3,106	$	6,801	$	7,739	$	2,370	$	2,818
XMT-1592 external costs										1,174		—
XMT-1522 external costs		305		4,646		2,267		11,347		—		978
Preclinical and discovery costs		4,994		1,590		13,383		3,434		1,507		4,108
Internal research and development costs		6,209		5,838		20,159		17,578		7,168		7,239
Total research and development costs	$	13,701	$	15,180	$	42,610	$	40,098	$	12,219	$	15,143

The successful development of our product candidates is highly uncertain. As such, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development of our product candidates. We are also unable to predict when, if ever, material net cash inflows will

~~Table of Contents~~

commence from the development efforts associated with our product candidates. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:

successful completion of preclinical studies and IND-enabling studies;

successful enrollment in and completion of clinical trials;

receipt of marketing approvals from applicable regulatory authorities;

establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;

Table of Contents

obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;

commercializing the product candidates, if and when approved, whether alone or in collaboration with others; and

continued acceptable safety profile of the drugs following approval.

A change in the outcome of any of these variables with respect to the development, manufacture or commercialization of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate.

General and administrative expenses

General and administrative expenses consist primarily of salaries and other employee-related costs, including stock-based compensation, for personnel in executive, finance, accounting, ~~information technology,~~ business development, legal operations, information technology and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.

We anticipate that our general and administrative expenses will increase in the future to support continued research and development activities, including increased costs related to the hiring of additional personnel, fees to outside consultants and patent costs, among other expenses.

Other income (expense)

Other income (expense) consists primarily of interest income earned on cash equivalents and marketable securities. Interest expense is related to borrowings under the credit facility that we entered into on May 9, 2019, with Silicon Valley Bank. ~~It bears~~These borrowings bear a floating per annum rate interest, as well as a final payment of 5% of the amounts drawn, that is being recorded as interest expense over the term through the maturity date using the effective-interest method. Also included in interest expense is the amortization of the deferred financing costs and the accretion of debt discount relating to the credit facility.

~~Critical accounting policies and estimates~~

Our management's discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates, if any, will be reflected in the financial statements prospectively from the date of change in estimates. There were no material changes to our critical accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on

2827

Table of Contents

~~March 8, 2019, with the exception of our critical accounting policies related to the adoption of ASC 842,~~ ~~Leases, effective January 1, 2019, as described in Note 2 to our consolidated financial statements included herein.~~

Results of Operations

Comparison of the three months ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~

The following table summarizes our results of operations for the three months ended ~~September 30, 2019~~March 31, 2020 and ~~2018:~~2019:


	Three months ended						Three months ended
	September 30,						March 31,
(in thousands)	2019		2018		Dollar Change		2020		2019		Dollar Change
Collaboration revenue	$	844	$	2,151	$	(1,307)	$	11	$	41,035	$	(41,024)
Operating expenses:
Research and development		13,701		15,180		(1,479)		12,219		15,143		(2,924)
General and administrative		4,436		4,380		56		4,936		4,443		493
Total operating expenses		18,137		19,560		(1,423)		17,155		19,586		(2,431)
Other income (expense):
Interest income		608		340		268		306		452		(146)
Interest expense		(107)		—		(107)		(88)		—		(88)
Total other income (expense), net		501		340		161		218		452		(234)
Net loss	$	(16,792)	$	(17,069)	$	277
Net income (loss)							$	(16,926)	$	21,901	$	(38,827)

Collaboration Revenue

Collaboration revenue was ~~$0.8~~immaterial during the three months ended March 31, 2020 and $41.0 million during the three months ended ~~September 30, 2019, compared to $2.2~~March 31, 2019. The decrease in collaboration revenue was primarily a result of the termination of the Takeda agreements and the recognition of the remaining deferred revenue of $40.0 million in the first quarter of 2019. Additionally, during the three months ended ~~September 30, 2018. The decrease~~March 31, 2019, collaboration revenue of ~~$1.3~~$1.0 million was ~~primarily a result of a decrease in services performed in support of partner programs for Asana BioSciences and~~recognized related to the Merck KGaA ~~Agreements.~~Agreement and Merck KGaA Supply Agreement.

Research and Development Expense

Research and development expense ~~was $13.7~~decreased by $2.9 million from $15.1 million for the three months ended ~~September 30,~~March 31, 2019 ~~compared~~ to ~~$15.2~~$12.2 million for the three months ended ~~September 30, 2018.~~ March 31, 2020.

The ~~overall~~ decrease ~~of $1.5 million~~in research and development expense was primarily ~~related~~attributable to ~~a decrease in~~the following:

a decrease of $1.4 million related to manufacturing activities for XMT-1536;

a decrease of $1.2 million because of an upfront payment in 2019 for a technology license fee and timing of research efforts;

a decrease of $0.8 million related to the development and manufacturing activities for XMT-1522; and

a decrease of $0.7 million to support partner programs.

These decreased costs ~~of $5.5 million for XMT-1536 and XMT-1522 programs,~~were partially offset by the following:

~~$2.4~~an increase of approximately $0.9 million ~~increase in manufacturing costs for preclinical and discovery efforts associated with our next ADC clinical candidate;~~

~~$0.5 million increase in costs for advancement of companion diagnostic development efforts for the NaPi2B biomarker;~~

~~$0.6 million increase attributable~~related to ~~a milestone paid upon dosing of the first patient in the expansion cohort of the~~ XMT-1536 clinical ~~trial;~~and regulatory expenses; and

~~$0.4~~an increase of $0.3 million ~~increase attributable~~related to ~~employee compensation, including stock-based compensation expense.~~advancement of companion diagnostic development efforts for the NaPi2b biomarker.

We expect our research and development expenses to increase as we continue our clinical development of XMT-1536 and XMT-1592 and continue to advance our preclinical product candidate pipeline and invest in improvements in our ADC technologies.

~~General and Administrative Expense~~

~~General and administrative expense was approximately $4.4 million during the three months ended September 30, 2019 and 2018. General and administrative expense remained flat due to the following:~~

~~$0.6 million in increased employee compensation, including stock-based compensation expense;~~

2928

Table of Contents

General and Administrative Expense

General and administrative expense increased by $0.5 million from $4.4 million during the three months ended March 31, 2019 to $4.9 million during the three months ended March 31, 2020. The increase in general and administrative was primarily attributable to an increase in the valuation of stock-based awards granted to employees, resulting in higher stock compensation expense.

~~$0.6 million in decreased consulting and professional fees.~~

We expect that our general and administrative expense will increase in ~~the~~ future ~~to support continued research and development activities~~periods as we expand our operations. These increases will likely include legal, auditing and filing fees, additional insurance premiums and general compliance and consulting expenses.

Total Other Income (Expense), net

~~Other~~Total other income (expense), net was ~~$0.5~~$0.2 million and ~~$0.3~~$0.5 million for the three months ended ~~September 30,~~March 31, 2020 and 2019, ~~and September 30, 2018,~~ respectively. Other income consists primarily of interest income on cash equivalents and short-term marketable securities, which ~~increased $0.3~~decreased $0.1 million due to ~~higher~~lower investable balances for the three months ended ~~September 30, 2019. Interest expense was related to our outstanding borrowings under the credit facility.~~

~~Comparison of the nine months ended September 30, 2019 and 2018~~

~~The following table summarizes our results of operations for the nine months ended September 30, 2019 and 2018:~~

Nine months ended

September 30,

(in thousands)

2019

2018

Dollar Change
Collaboration revenue

$
42,081

$
9,405

$
32,676
Operating expenses:

Research and development

42,610

40,098

2,512
General and administrative

13,072

12,181

891
Total operating expenses

55,682

52,279

3,403
Other income (expense):

Interest income

1,785

1,049

736
Interest expense

(146)

—

(146)
Total other income (expense), net

1,639

1,049

590
Net loss

$
(11,962)

$
(41,825)

$
29,863

~~Collaboration Revenue~~

Collaboration revenue was $42.1 million during the nine months ended September 30, 2019, compared to $9.4 million during the nine months ended September 30, 2018, an increase of $32.7 million, primarily as a result of the termination of the Takeda agreements and the recognition of the remaining deferred revenue of $40.0 million. Additionally, revenue of $2.1 million was recognized for the Merck KGaA Agreement and Merck KGaA Supply Agreement in the nine months ended September 30, 2019. This compares to the revenue recognized during the nine months ended September 30, 2018 for support of partner programs with Takeda, Merck KGaA and Asana BioSciences of $7.9 million and recognition of a milestone of $1.5 million achieved upon completion of a GLP toxicology study by Asana BioSciences.

~~Research and Development Expense~~

Research and development expense was $42.6 million for the nine months ended September 30, 2019, compared to $40.1 million for the nine months ended September 30, 2018. The overall increase of $2.5 million was primarily attributable to the following:

~~$0.5 million increase in costs for advancement of companion diagnostic development efforts for the NaPi2B biomarker;~~

~~$0.7 million increase in lab consumables and facilities costs;~~

~~$0.6 million increase attributable to a milestone paid upon dosing of the first patient in the expansion cohort of the XMT-1536 clinical trial; and~~

~~$1.7 million increase in employee compensation, including stock-based compensation expense.~~

~~Table of Contents~~

~~These increased costs were primarily offset by $1.2 million in decreased clinical and regulatory expenses related to XMT-1522 program costs.~~

We expect our research and development expenses to increase as we continue our clinical development of XMT-1536 and continue to advance our preclinical product candidate pipeline and invest in improvements in our ADC technologies.

~~General and Administrative Expense~~

General and administrative expense was $13.1 million for the nine months ended September 30, 2019, compared to $12.2 million for the nine months ended September 30, 2018. The increase of $0.9 million was primarily attributable to $1.4 million in increased employee compensation, including stock-based compensation expense. This increased cost was offset by $0.6 million in decreased consulting and professional fees.

We expect that our general and administrative expense will increase in the future to support continued research and development activities. These increases will likely include legal, auditing and filing fees, additional insurance premiums and general compliance and consulting expenses.

~~Other Income (Expense)~~

Other income (expense), net, was $1.6 million and $1.0 million for the nine months ended September 30, 2019 and September 30, 2018, respectively. Other income consists primarily of interest income on cash equivalents and marketable securities, which increased $0.7 million due to higher investable balances for the nine months ended September 30, 2019.March 31, 2020. Interest expense of $0.1 million in the first quarter of 2020 was related to our outstanding borrowings under the credit facility.

Liquidity and Capital Resources

Sources of Liquidity

Since our initial public offering in July 2017, we have financed our operations primarily with the proceeds from that offering and our 2019 follow-on public offering. The follow-on public offering was completed on March 5, 2019 and resulted in net proceeds of $92.2 million. On May 8, 2019, the Company entered into a term-loan agreement for up to $20.0 million, of which $5.0 million was funded in connection with the execution of the agreement. No additional amounts have been drawn since the initial $5.0 million. As of ~~September 30, 2019,~~March 31, 2020, we had cash, cash equivalents and marketable securities of ~~$112.0~~$78.4 million.

On July 2, 2018, we established an ATM pursuant to which we are able to offer and sell up to $75.0 million of our common stock from time to time at prevailing market prices. As of ~~September 30, 2019,~~March 31, 2020, we had not sold any shares under the ATM and had $75.0 million of availability under the program. On April 7, 2020, we sold 8.9 million and 2.0 million shares of common stock at$5.59 per share and $7.74 per share, respectively, to raise gross proceeds of approximately $65 million.

Cash Flows

The following table provides information regarding our cash flows for the ~~nine~~three months ended ~~September 30, 2019~~March 31, 2020 and ~~2018:~~2019:


	Nine months ended				Three months ended
	September 30,				March 31,
(in thousands)	2019		2018		2020		2019
Net cash used in operating activities	$	(55,168)	$	(39,312)	$	(21,246)	$	(24,687)
Net cash provided by (used in) investing activities		(43,793)		73,472
Net cash provided by financing activities		97,473		853
Net cash provided by investing activities						19,435		10,128
Net cash provided by (used in) financing activities						(90)		92,204
Increase (decrease) in cash, cash equivalents and restricted cash	$	(1,488)	$	35,013	$	(1,901)	$	77,645

Net Cash Used in Operating Activities

Net cash used in operating activities was $21.2 million for the ~~nine~~three months ended ~~September 30,~~March 31, 2020 and primarily consisted of a net loss of $16.9 million adjusted for changes in our net working capital and other non-cash items including stock-based compensation of $1.6 million and depreciation of $0.2 million. Net cash used in operating activities was $24.7 million for the three months ended March 31, 2019 ~~was $55.2~~and primarily consisted of a net income of $21.9 million adjusted for non-cash items including the decrease in deferred revenue of $41.0 million primarily related to the Takeda agreements, stock-based compensation of $1.2 million and depreciation of $0.3 million, as ~~compared to $39.3 million during the nine months ended September 30, 2018. The increase was due primarily to an increase~~well as change in ~~operating expenses and the timing of payments made to vendors.~~our net working capital.

3129

Table of Contents

Net Cash Provided by ~~(Used in)~~ Investing Activities

Net cash used in investing activities was $43.8 million during the nine months ended September 30, 2019 and consisted primarily of purchases of marketable securities, partially offset by maturities of marketable securities. Net cash provided by investing activities was ~~$73.5~~$19.4 million and $10.1 million during the ~~nine~~three months ended ~~September 30, 2018~~March 31, 2020 and 2019, respectively, and consisted primarily of maturities of marketable securities.

Net Cash Provided by (Used in) Financing Activities

Net cash used in financing activities was $0.1 million during the three months ended March 31, 2020 as compared to net cash provided by financing activities ~~was $97.5~~of $92.2 million during the ~~nine~~three months ended ~~September 30, 2019 as compared to $0.9 million during~~March 31, 2019. During the ~~nine~~three months ended ~~September 30, 2018.~~March 31, 2020 cash used in financing activities consisted primarily of the payment of $0.2 million of debt issuance costs, offset by $0.1 million in proceeds from the exercise of stock options. During the ~~nine~~three months ended ~~September 30,~~March 31, 2019 cash provided by financing activities consisted primarily of the proceeds from the Company’s follow-on public ~~offering and issuance of debt. During the nine months ended September 30, 2018, cash provided by financing activities resulted primarily of the proceeds from exercises of stock options.~~offering.

Funding Requirements

We expect our cash expenditures to increase in connection with our ongoing activities, particularly as we continue the research and development of, ~~continue~~initiate clinical ~~trials~~studies of, and seek marketing approval for our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. ~~Accordingly, we~~

We believe our currently available funds will ~~need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would~~ be ~~forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.~~

~~We currently expect that our cash, cash equivalents, and marketable securities will enable us~~sufficient to fund our ~~operating plan~~existing cash flow requirements and our operations at their currently planned levels through at least ~~mid-2021. In addition,~~the twelve months following the filing of this Quarterly Report on Form 10-Q. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we ~~have access to an additional line of credit of $15.0 million.~~could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:

the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical ~~trials~~studies for our product candidates;

the scope, prioritization and number of our research and development programs;

the costs, timing and outcome of ~~reviews~~regulatory review of our product ~~candidates by regulatory agencies;~~candidates;

our ability to establish and maintain collaborations on favorable terms, if at all;

the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we obtain;

the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical ~~trial~~study costs under future collaboration agreements, if any;

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property‑related claims;

the extent to which we acquire or in‑license other product candidates and technologies;

the costs of securing manufacturing arrangements for clinical and commercial production; and

the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates.

3230

Table of Contents

Identifying potential product candidates and conducting preclinical testing and clinical ~~trials~~studies is a time‑consuming, expensive and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve drug sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, strategic partnerships and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. We have access to an additional line of credit of $15.0 million under the Credit Facility along with funds to be earned in connection with our agreements with Merck KGaA and Asana BioSciences, if development activities are successful under those agreements. Future additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

If we raise funds through additional strategic partnerships or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Off‑Balance Sheet Arrangements

We did not have, during the periods presented, and we do not currently have, any off‑balance sheet arrangements, as defined under applicable Securities and Exchange Commission rules.

Critical accounting policies and significant judgments and estimates

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market ~~risk related~~risk-related to changes in interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments, including cash ~~and cash~~ equivalents and ~~short-term~~ marketable securities are ~~in a money market fund that invests~~invested in U.S. Treasury ~~obligations. Due~~obligations, commercial paper and corporate bonds. However, we believe that due to the short-term duration of our investment portfolio and ~~the low risk~~low-risk profile of our investments, ~~if market interest rates were to increase immediately and uniformly by~~an immediate 100 basis points ~~or one percentage point, from levels at September 30, 2019, the~~ change in ~~the net fair value of our interest-sensitive marketable securities~~interest rates would not have a material effect on the fair market value of our investments portfolio.

We are currently not exposed to market risk related to changes in foreign currency exchange rates, but we may contract with vendors that are located in Asia and Europe and may be subject to fluctuations in foreign currency rates at that time.

~~Inflation generally affects us by increasing our cost~~

Table of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the three or nine months ended September 30, 2019 and 2018.Contents

Item 4. Controls and Procedures

Management’s Evaluation of our Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act), that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies

~~Table of Contents~~

its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of ~~September 30, 2019,~~March 31, 2020, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon such evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the ~~period covered by this Quarterly Report on Form 10-Q~~three months ended March 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

3432

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the ~~end~~date of ~~the period covered by~~ this ~~report,~~Quarterly Report on Form 10-Q, we ~~did~~do not believe we ~~were~~are party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A. Risk Factors

Risk Factors

~~There~~Other than as disclosed below, there have been no material changes to the Company’s risk factors as set forth in Part I, Item 1A of the Company’s Annual Report on Form 10-K, as filed with the SEC on February 28, 2020.

Our business is subject to risks arising from the outbreaks of disease, such as epidemics or pandemics, including the ongoing COVID-19 pandemic.

On January 30, 2020, the World Health Organization (the “WHO”) announced a global health emergency because of COVID-19, the strain of novel coronavirus that originated in Wuhan, China and has since spread globally. In March ~~8, 2019.~~2020, the WHO declared the COVID-19 outbreak a pandemic and recommended containment and mitigation measures worldwide. On March 13, 2020, President Trump announced a National Emergency relating to the disease. The widespread infection in the United States and abroad has caused significant volatility and uncertainty in U.S. and international markets, which could result in a prolonged economic downturn that may disrupt the Company’s business, including by adversely affecting our ability to conduct financings on terms acceptable to us, if at all.

In addition, we may experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:

Our clinical trials may be adversely affected, delayed or interrupted, including, for example, site initiation, patient recruitment and enrollment, availability of clinical trial materials, and data analysis. Some patients and clinical investigators may not be able to comply with clinical trial protocols and patients may choose to withdraw from our studies or we may have to pause enrollment or we may choose to or be required to pause enrollment and or patient dosing in our ongoing clinical trials in order to preserve health resources and protect trial participants. It is unknown how long these pauses or disruptions could continue.

We currently rely on third parties to, among other things, manufacture raw materials, manufacture our product candidates for our clinical trials, shipping of investigation drugs and clinical trial samples, perform quality testing and supply other goods and services to run our business. If any such third party in our supply chain for materials are adversely impacted by restrictions resulting from the coronavirus pandemic, including staffing shortages, production slowdowns and disruptions in delivery systems, our supply chain may be disrupted, limiting our ability to manufacture our product candidates for our clinical trials and conduct our research and development operations.

We have requested that most of our personnel work remotely, restricted on-site staff to only those personnel and contractors who must perform essential activities that must be completed on-site and limited the number of staff in any given research and development laboratory. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors.

Table of Contents

Our employees and contractors conducting research and development activities may not be able to access our laboratory for an extended period of time as a result of the closure of our offices and the possibility that governmental authorities further modify current restrictions. As a result, this could delay timely completion of preclinical activities, including completing Investigational New Drug (IND)-enabling studies or our ability to select future development candidates, and initiation of additional clinical trials for other of our development programs.

Health regulatory agencies globally may experience disruptions in their operations as a result of the coronavirus pandemic. The U.S. Food and Drug Administration, or FDA, and comparable foreign regulatory agencies may have slower response times or be under-resourced to continue to monitor our clinical trials and, as a result, review, inspection, and other timelines may be materially delayed. It is unknown how long these disruptions could continue, were they to occur. Any prolongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates. For example, regulatory authorities may require that we not distribute a product candidate lot until the relevant agency authorizes its release. Such release authorization may be delayed as a result of the coronavirus pandemic and could result in delays to our clinical trials.

The trading prices for our common shares and other biopharmaceutical companies have been highly volatile as a result of the coronavirus pandemic. As a result, we may face difficulties raising capital through sales of our common shares or such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the coronavirus could materially and adversely affect our business and the value of our common shares.

The coronavirus pandemic continues to evolve, rapidly. The ultimate impact of the coronavirus pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, the ultimate geographic spread of the disease, additional or modified government actions, new information that will emerge concerning the severity and impact of COVID-19 and the actions taken to contain coronavirus or address its impact in the short and long term, among others. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy.

Table of Contents

Item 6. Exhibits.


EXHIBIT 3.1	-	Fifth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on July 10, 2017).

EXHIBIT 3.2	-	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, filed on July 10, 2017).

EXHIBIT 10.1	-	~~First Amendment~~Seventh Lease Extension and Modification Agreement to the ~~License, Development~~Lease Between Rivertech Associates II LLC and ~~Commercialization Agreement~~Mersana Therapeutics, Inc. dated ~~August 19, 2019,~~March 10 2020, by and between Mersana Therapeutics, Inc. and ~~Recepta Biopharma, S.A.~~Rivertech Associates II LLC.

EXHIBIT 10.2	-	Offer Letter, by and between Mersana Therapeutics, Inc. and Dirk Huebner, dated November 5, 2018.

EXHIBIT 10.3	-	Offer Letter, by and between Mersana Therapeutics, Inc. and Brian DeSchuytner, dated June 10, 2019.

EXHIBIT 31.1	-	Rule 13a—14(a) / 15d—14(a) Certifications — Chief Executive Officer.

EXHIBIT 31.2	-	Rule 13a—14(a) / 15d—14(a) Certifications — Principal Financial Officer.

EXHIBIT 32.1	-	Section 1350 Certifications.

EXHIBIT 101.INS	-	XBRL Instance Document.

EXHIBIT 101.SCH	-	XBRL Taxonomy Extension Schema Document.

EXHIBIT 101.CAL	-	XBRL Taxonomy Extension Calculation Linkbase Document.

EXHIBIT 101.DEF	-	XBRL Taxonomy Extension Definition Linkbase Document.

EXHIBIT 101.LAB	-	XBRL Taxonomy Extension Label Linkbase Document.

EXHIBIT 101.PRE	-	XBRL Taxonomy Extension Presentation Linkbase Document.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Mersana Therapeutics, Inc.

Dated: ~~November 6, 2019~~May 8, 2020	By:	/s/ Anna Protopapas
		Anna Protopapas
		President and Chief Executive Officer

Dated: ~~November 6, 2019~~May 8, 2020	By:	/s/ Brian DeSchuytner
		Brian DeSchuytner
		Senior Vice President, Finance & Product Strategy


	Nine months ended
	September 30, 2019
Operating leases:
Operating lease right-of-use assets	$	3,059
Operating lease liabilities, current		2,145
Operating lease liabilities		1,257

Finance leases:
Property and equipment, gross	$	429
Property and equipment, accumulated depreciation		(50)
Other liabilities, current		85
Other liabilities		299

Weighted-average remaining lease term:
Operating leases		1.6 years
Finance leases		4.0 years

Weighted-average discount rate:
Operating leases		10.3%
Finance leases		6.9%


	Nine months ended
	September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	1,685
Operating cash flows from finance leases		14
Financing cash flows from finance leases		58
Right-of-use assets obtained in exchange for lease obligations:
Operating leases		4,369
Finance leases		429